Comparison of intestinal APC subsets from homeostatic and immunostimulatory environments by Hilligan, Kerry
Comparison of intestinal 
APC subsets from 
homeostatic and 
immunostimulatory 
environments 
 
Kerry Hilligan 
2014 
 
 
 
A thesis submitted to the Victoria University of Wellington in 
fulfilment of the requirements for the degree of Master of Biomedical 
Science 
 
  ii 
Abstract 
 
Antigen presenting cells (APC) including dendritic cells (DC) play a key role in the initiation 
and direction of adaptive immune responses. Acting as sentinels in the tissue, DC sample 
antigen and traffic to the local lymph node where they present antigen to naïve T cells. The 
signals DC provide to naïve T cells determines the functional fate of the T cell and therefore, 
the type of immune response generated.  
 
At mucosal sites, such as the intestine, immune responses need to be carefully regulated due 
to the high antigenic load. For this reason, intestinal immune cells are highly specialised to 
prevent immune activation to innocuous antigens while still holding the capacity to induce 
potent responses to pathogenic microbes and helminths. Oral administration of antigen is 
associated with tolerance and the generation of FoxP3+ regulatory T cells (Tregs). 
Specialised lamina propria (LP) resident APC are required for the initiation of Treg 
differentiation in the mesenteric lymph nodes (MLN) through production of chemical 
mediators such as retinoic acid (RA). Ablation of these populations or restricted trafficking 
prevents the development of Tregs in mouse models thus supporting the essential role of 
APC in maintaining intestinal homeostasis. 
 
During infection, APC promote the induction of adaptive immune responses which 
neutralise threats. However, the APC subsets involved in this are not well defined. 
Pathologies such as food allergy and inflammatory bowel disease are thought to arise due to 
the development of aberrant immune responses. Food allergy can be modelled in mice using 
the mucosal adjuvant cholera toxin (CT) which has been shown to drive immunity to co-
delivered antigens and is associated with the generation of IL-4 producing T helper 2 cells. 
Understanding the APC subsets involved in the initiation of intestinal immune responses 
could help in the development of targeted therapies for inflammatory bowel conditions. 
 
In this thesis, I show that oral administration of CT is followed by the appearance of a novel 
phenotype of DC in the intestinal LP and MLN. These DC differ functionally from DC at 
steady-state and may contribute to the generation of IL-4 producing T cells observed in the 
LP, MLN and spleen following oral administration of CT.  
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1.1. APC: the link between innate and adaptive immunity 
 
The two arms of the immune system play very different but nevertheless, essential roles to 
host defence. The key regulators of cross-talk between the innate and adaptive systems are 
antigen presenting cells (APC). Dendritic cells (DC) are described as professional APC due 
to their superior ability to initiate and direct adaptive immune responses compared to other 
APC such as macrophage (Mφ) and B cells 1, 2. It is now understood that DC are innate 
immune cells that act as sentinels, monitoring the tissue for danger or pathogen associated 
motifs. Following acquisition of antigen, DC migrate to the lymph node where they present 
antigen to T cells and drive T cell proliferation and differentiation 3.  
 
The innate immune system provides the first line of defence against pathogens. Cells of the 
innate immune system are equipped with pathogen recognition receptors (PRR) including 
toll-like receptors (TLR) and NOD-like receptors (NLR) which enables them to detect signs 
of microbial invasion. Innate cells respond by producing cytokines, chemokines and 
antimicrobial proteins in order to drive inflammation, neutralise threats and activate cells of 
the adaptive immune system 4.  
 
The adaptive immune system consists of T and B lymphocytes which are able to target 
threats more specifically. Genetic shuffling of antigen receptor components allows for the 
generation of a repertoire of adaptive immune cells capable of responding to vast numbers 
of individual antigens. Upon infection, activation of adaptive immunity results in 
proliferation of highly specific effector cells that can directly kill infected cells or provide 
cytokines to recruit populations of other immune cells 5. In addition, following the resolution 
of the infection, small numbers of these effector cells remain in circulation as memory cells 
allowing for faster, more effective responses to future infection 1.  
 
1.1.1. Activation and licensing of DC 
 
Primarily the role of DC is to monitor peripheral tissues and sample environmental antigen 
by phagocytosis and receptor-mediated endocytosis. Antigen is processed and displayed on  
the cell surface on major histocompatibility complex (MHC) molecules. Exogenous antigen 
is displayed on MHCII molecules to specifically activate CD4 T cells while endogenous 
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antigen is presented on MHCI to CD8 T cells. Importantly, specific subsets of DC are able 
to cross-present exogenous antigen to CD8 cytotoxic T cells via MHCI molecules 6.  
 
At steady-state, DC traffic constitutively to the draining lymph node to replenish other DC 
populations and present antigen to T cells in order to maintain immunological tolerance to 
self antigens 7. On the other hand, sensing of pathogen or danger associated motifs through 
TLRs and NLRs leads to immune activation 6. Signalling through PRRs leads to DC 
activation and licensing through upregulation of co-stimulatory molecules CD80/86 8 and 
lymph node homing receptor CCR7 9. DC subsequently traffic to the lymph node and 
interact with T cells promoting the initiation of adaptive immune responses. 
 
 
1.1.2. DC regulate T cell proliferation and differentiation 
 
T cells require three signals from DC to proliferate and differentiate into appropriate 
effector cells (Fig. 1.1.). Firstly, DC present antigen on MHC molecules to T cells expressing 
the T cell receptor (TCR) specific for that antigen. This signal allows for activation and 
expansion of the T cell capable of recognising and inducing the appropriate response to the 
microbial agent. Secondly, mature DC express increased levels of co-stimulatory molecules, 
including CD80 and CD86 which bind to CD28 on naïve T cells. This interaction ensures 
sufficient T cell activation and prevents permanent T cell unresponsiveness known as T cell 
anergy 8, 10. Finally, environmental cues condition DC to instruct differentiation of T cells to 
the appropriate effector cell type through production of soluble chemical mediators, such as 
cytokines, and additional receptor-ligand interactions. Following these signals, naive T cells 
become effector cells capable of elaborating effector functions, including cytotoxicity, 
cytokine production and immune suppression. Cytotoxic T cells directly kill infected cells 
through perforin and/or granzyme mechanisms 11, 12, 13 whereas helper T cells produce 
cytokines which can promote antibody production by B cells, activation and recruitment of 
immune cells or inhibit proliferation and activation of an immune response 6. Both CD4+ 
and CD8+ T cells have the capacity to adopt either of these functions, however, CD8+ T 
cells are primarily associated with cytotoxic activity whereas CD4+ T helper (Th) cells are 
primarily associated with cytokine production. 
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There are at least four phenotypes of effector Th cells, which can be characterised by their 
distinct effector functions and cytokine profiles 1, 14. DC production of IL-12 promotes Th1 
differentiation 15 and production of cytokines including IL-6 and TGFβ promote Th17 
differentiation 16, 17. Th1 and Th17 cells, characterised by their production of IFNγ and IL-17 
respectively, mount responses against bacteria, protozoa, viruses and fungi 1, 18. Th1 cells 
activate innate cells such as Mφ and are capable of inducing effector functions by CD8 
cytotoxic T cells and B cells 19. Th17 cells play an important role in resolving bacterial and 
fungal infections through recruitment and activation of neutrophils 20. In contrast to Th1 
and Th17 immunity, little is known about how DC induce Th2 responses in vivo 21, 22, 23. 
Interestingly, environmental signals have been shown to induce expression of OX40L on 
DC which, upon interaction with T cell OX40, promotes Th2 differentiation. This suggests a 
role for receptor mediated interactions, in addition to soluble mediators, in Th2 polarisation 
24. Th2 cells produce IL-4, IL-5 and IL-13 and target multicellular pathogens such as 
helminths through recruitment and activation of mast cells, eosinophils and basophils 25. 
Furthermore, Th2 immunity is strongly associated with allergic diseases and chemical 
mediators released by mast cells are thought to be responsible for causing allergic symptoms. 
In addition to effector Th cells, naïve CD4+ T cells can differentiate into Tregs, which are 
generated to maintain tolerance to self and innocuous antigens. There are two subtypes of 
Tregs: natural Tregs which develop in the thymus and inducible Tregs which develop from 
naïve Th cells in the periphery 26. Inducible Tregs are commonly found at mucosal sites 
where immune cells are readily exposed to environmental antigen. Tregs produce anti-
inflammatory cytokines such as IL-10 and prevent inappropriate immune activation and 
assist with the resolution of inflammatory responses 27. Importantly, Th cell subsets are not 
fixed and rigid but rather consist of a heterogeneous and plastic population that can alter 
their cytokine profile and may even produce multiple cytokines in response to environmental 
signals 28. The extent of this plasticity depends on the differentiation state 29, 30 and phenotype 
of the T cell. For example, Th17 31, 32 and Treg 33, 34 cells are capable of altering their cytokine 
profile throughout their differentiation process whereas Th1 and Th2 cells are thought to 
have a more stable phenotype and are less likely to change their cytokine profile once 
differentiation has been initiated 30.  Furthermore, recent evidence suggests there may be 
additional Th subsets that produce cytokines such as IL-9 35 and IL-22 36, although the roles 
these subsets play in immune responses are currently not well understood. 
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Overall, DC provide a crucial link between innate and adaptive immunity and are responsible 
for initiating adaptive responses. Environmental signals received by DC and the subsequent 
signals between DC and T cells are important determinants of the type of immune response 
generated. Therefore, dysfunction in the signalling pathways leading to DC activation and 
signalling between DC and T cells can induce aberrant immune responses and subsequent 
pathology. Harnessing the power of the DC through targeted vaccines can set the stage for 
initiating appropriate immune responses. 
 
 
 
Figure 1.1: DC direct T cell proliferation and differentiation  
APC, such as DC, induce antigen specific T cell activation and expansion through presentation of 
antigen on MHC molecules and co-stimulation. Chemical mediators, such as cytokines, and 
additional receptor mediated interactions between the DC and T cell determine the effector cell 
phenotype the T cell will adopt.  
Chapter 1: General Introduction  
 
6 
 
1.1.3. Origin and function of DC populations 
 
In 1990, CD11c was recognised as a marker expressed solely on murine DC 37. The accuracy 
of using CD11c to identify DC is currently being disputed 38, with examples of CD11c 
expression overlapping with Mφ populations in the spleen 39, lung 40, kidney 41 and intestine 42 
and with CD8+ Tregs 43. Nevertheless, CD11c remains a useful tool to identify DC in 
conjunction at with expression of MHCII molecules. There are at least three populations of 
DC that are developmentally distinct and specialise at recognising different classes of 
microbial agents due to their varying repertoires of PRRs 10.  
 
Conventional DC (cDC) originate from common myeloid progenitors from the bone 
marrow and can be further classified into peripheral tissue resident migratory DC or 
lymphoid tissue resident DC. At steady-state, migratory and lymphoid cDC can be identified 
by their differential expression of CD11c and MHCII. The migratory DC population express 
a CD11cint MHCIIhi phenotype while the lymphoid DC population express a CD11chi 
MHCIIint phenotype 44. cDC can be divided into subsets by expression of additional cell 
surface markers including CD11b, CD103, CD4 and CD8α and have differential abilities to 
prime CD4 and CD8 T cells 45. Migratory DC are able to acquire antigen in the tissue, traffic 
to local lymph nodes and initiate T cell responses. In contrast, lymphoid DC remain in the 
lymphoid tissue and respond to local stimuli 2. 
 
Plasmacytoid DC (pDC) are found in peripheral tissues and lymphoid organs. They are 
identified by expression of B220, Ly6C, Siglec H and lower expression of CD11c compared 
to cDC 46, 47. The best characterised function of pDC is to recognise viral motifs through 
TLR7 and TLR9. Following activation, pDC induce potent antiviral responses by initiating 
both innate and adaptive responses through production of type I interferons 48. In addition, 
immature pDC have been implicated in driving tolerogenic responses in mice and humans 
through production of IL-10 27, 46. 
 
More recently, a subset of inflammatory monocyte-derived DC (moDC) has been identified. 
These cells are derived from monocytes circulating in the blood and differentiate into DC at 
sites of inflammation and are capable of antigen uptake and inducing T cell proliferation. 
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MoDC are identified by their expression of the monocyte markers Ly6C and CD64 in 
conjunction with the DC markers CD11c and MHCII 49, 50. MoDC have been shown to be 
key players in the initiation of adaptive responses in vaccination and tumour immunotherapy 
contexts 50, 51 and also in allergic airway disease 49.  
 
 
Figure 1.2: Lineages of DC 
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1.2. The intestinal immune system 
 
The immune system at mucosal sites, such as the intestine, requires tight regulation due to 
the constant exposure to foreign and microbial antigens from food proteins and the 
commensal microbiota. Development of effector responses to these antigens is associated 
with pathology such as food allergy and inflammatory bowel disease (see Section 1.2.3.). 
Therefore, the intestinal immune system is well adapted to develop tolerance to food 
proteins and commensal bacteria in order to prevent immune activation and maintain 
homeostasis. Importantly, despite the tolerogenic environment in the intestine, immune cells 
need to maintain the capacity to recognise and mount responses to pathogens. Highly 
specialised APC play key roles in regulating intestinal immune homeostasis by differentiating 
between innocuous antigens and pathogens (see Section 1.2.2.) and subsequently initiating 
appropriate responses. Therefore, a dichotomy exists in which recognition of antigen in the 
intestine can lead to either tolerance or immunity. Further understanding is required to 
determine whether environmental cues or activation of specific APC populations lead to the 
development of intestinal immunity. 
 
 
1.2.1. Intestinal immune homeostasis 
 
Intestinal immune homeostasis is maintained through a number of active processes which 
include oral tolerance 52, production of secretory IgA by B cells 53 and release of 
antimicrobial peptides and mucous by Paneth and goblet cells respectively 54. Specialised 
populations of APC, unique to the intestine, are vital for promoting the development of oral 
tolerance 55, 56, 57, 58. Therefore, the primary focus of this section will be on oral tolerance.  
 
Tolerance is a term used to describe immunological unresponsiveness, or lack of an effector 
response, to a specific antigen 59. Oral tolerance involves two major components: the 
development of antigen specific Tregs 60 and the development of anergic T cells 61 to orally 
administered antigen. Firstly, Tregs play an important role in the suppression of 
inappropriate immune responses to self and innocuous antigens 60. At mucosal sites, Tregs 
are responsible for creating a non-inflammatory environment by production of the cytokines 
IL-10 and TGFβ 52. Exposure to antigens via the oral route induces antigen specific Tregs in 
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the LP, Peyer’s patches, MLN and at other peripheral sites 52. Depletion of Tregs by 
targeting FoxP3+ cells results in a failure to develop tolerance to oral administration of 
ovalbumin antigen 60. Secondly, oral tolerance can be achieved through T cell anergy 
(permanent non-responsiveness, usually due to activation with limited co-stimulation by 
CD80 and CD86 molecules) and deletion of food antigen specific T cells 52, 61. Interestingly, 
oral administration of antigen has been shown to result in tolerance not only locally but also 
systemically. For example, oral feeding of antigen prior to intraperitoneal immunisation with 
an adjuvant prevented a delayed hypersensitivity response upon antigen challenge in the ear 
pinna 55.  
 
In addition to T cell responses, intestinal immune homeostasis relies on physical defences 
that limit the interaction between luminal antigen and intestinal immune cells. A key 
component of this is the epithelial barrier which consists of a number of specialised cell 
types joined together by tight junctions 54. A double layer of mucous on the apical side of the 
epithelial barrier limits the access of luminal antigens to epithelial and immune cells 62 and 
acts as a scaffold for secretory IgA which further decreases the availability of antigen 53. 
Finally, for protection against immune activation to commensal bacteria, Paneth cells (a 
constituent of the epithelial barrier) continually release antimicrobial peptides into the lumen 
63. 
 
Furthermore, accumulating evidence suggests that the intestinal microbiome has a critical 
role in educating the intestinal immune system to promote tolerance at steady-state 64. Germ-
free mice are reared in a sterile environment and therefore are devoid of the natural 
microflora usually acquired at birth. These mice have been shown to spontaneously develop 
Th1 and Th17 cells 65. Signalling through TLRs is a possible mechanism by which 
commensals and immune cells communicate 66. This is supported by studies in which mice 
deficient in proteins involved in TLR signalling (MyD88 and Ticam1) had significantly lower 
number of Tregs upon colonisation compared to wildtype controls 65. Thus, the composition 
of the microbiota is likely to be important in maintaining immune balance 67.  
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1.2.2. Intestinal immunity 
 
While it is important that tolerance is maintained, the intestinal immune system needs to 
remain capable of inducing potent effector responses to eliminate pathogens. Due to the key 
role APC play in linking innate and adaptive immunity, it is likely environmental signals 
influence APC to drive either tolerogenic or effector responses. However, despite the wealth 
of recent research, it remains an enigma as to how intestinal APC are able to distinguish 
between innocuous antigens (such as food antigens and commensal microbes) and 
pathogens and subsequently mount the appropriate response.  
 
Despite the fact that commensal microbes and pathogenic bacteria have the same PRR 
ligands, intestinal APC maintain tolerance to commensals but induce effector responses to 
pathogens. As mentioned above, one key component in maintaining intestinal homeostasis 
was the epithelial barrier which prevented the invasion of luminal proteins and commensal 
microbes into the LP. Therefore, it is possible that only pathogenic bacteria are able to gain 
entry into the LP and interact with immune cells which subsequently initiate effector 
responses. In support of this hypothesis, epithelial cells have been shown to differentially 
express TLRs on their apical and basolateral surfaces with one study showing some TLRs 
are restricted to the basolateral surface 68. Several studies have shown TLR signalling is 
important for mobilisation and activation of intestinal APC in response to microbial stimuli 
69, 70, 71, 72, 73. However, other studies show non-invasive Salmonella is capable of recruiting but 
not maturing DC 74. Furthermore, some populations of intestinal APC extend transepithelial 
dendrites into the lumen and directly sample antigen and thus will be continually in contact 
with foreign antigen 71, 75, 76. Despite this, penetration by pathogenic strains through the 
epithelial barrier into the LP proves to be the best supported hypothesis on how effector 
responses are generated specifically towards pathogens in the intestine 77. 
 
In addition to bacterial invasion, it is also important to consider the complexity of the 
intestinal immune system and the likelihood that integration of signals from a number of cell 
types is required for the initiation of effector responses. Cross-talk between epithelial cells 
and APC has been implicated in regulating homeostasis 78 so it stands to reason that 
signalling between these cell types may also be involved in the generation of effector 
responses. In support of this, TLR signalling in both epithelial cells and APC was required 
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for mobilisation of APC following oral infection with Salmonella 72. Furthermore, ATP, a 
recognised danger signal, induced epithelial cell production of pro-inflammatory cytokines 
and chemokines and recruited neutraphils 79. In contrast, intestinal Mφ failed to produce pro-
inflammatory cytokines upon exposure to TLR ligands in vitro, suggesting that cross-talk 
between other immune cells and tolerogenic Mφ may play a role in shifting the balance 
between immune activation and tolerance 80, 81. Thus, further study is required to understand 
how immunity is initiated towards pathogens but not food proteins and commensals in the 
intestine. 
 
 
1.2.3. Inappropriate intestinal immunity: food allergy and IBD 
 
Careful balance between tolerance and immunity is required to maintain homeostasis. When 
this balance becomes dysregulated inappropriate immune responses can develop to harmless 
antigens. Two common examples of this are food allergy and inflammatory bowel disease 
(IBD). Both of these conditions have experienced a sharp increase in prevalence over the 
last decade and represent a major health concern 82, 83, 84, 85, 86. 
 
Food allergy 
 
Food allergy results from inappropriate immune activation of Th2 effector cells to specific 
food antigens. Th2 cells, characterised by their production of IL-4, IL-5 and IL-13, promote 
the production of antigen specific IgE antibodies which bind to the high affinity IgE 
receptor FcεR1 on the surface of mast cells and basophils. Upon subsequent exposure, food 
antigens bind to IgE leading to cross-linking of FcεR1 inducing mast cells and eosinophils 
release of inflammatory mediator molecules that are responsible for the symptoms 
associated with allergic disease 87. It is these molecules, including serotonin and platelet-
activating factor, that produce the symptoms of allergic diarrhoea and anaphylaxis in mouse 
models of food allergy 88. 
 
The processes that lead to allergic sensitisation and the initial development of Th2 cells are 
currently unknown and may occur at sites other than the intestine such as the skin 89. 
Despite this, alterations in the microbiota composition are likely to be playing a role 90. 
Perturbation in microbiota composition, specifically lack of species diversity, has been 
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associated with the development of atopic dermatitis, allergic rhinitis and other allergic 
diseases in children 91, 92, 93. Germ-free mice have higher serum IgE titres and are more 
susceptible to models of food allergy compared to littermate controls further supporting the 
role for commensals in intestinal immune regulation 94. 
 
Inflammatory bowel disease 
 
IBD is a class of pathologies characterised by chronic intestinal inflammation due to the 
induction of a strong Th1 response to commensal microbes 95, 96. Due to their roles in 
sampling and presentation of antigen, intestinal APC are thought to contribute to immune 
responses in instances of IBD 97 with murine colitis studies showing the accumulation of 
activated APC throughout the LP and MLN 98. Recent studies show these highly activated 
APC may be inflammatory DC derived from monocyte precursors that promote Th1 
differentation 99. However, it is not clear whether these activated APC are the primary 
drivers of inflammation or accumulate due to pro-inflammatory signals from other cell types. 
 
In addition to intestinal APC, the epithelial barrier and microbial composition may be factors 
in IBD pathogenesis. At steady-state, the epithelial barrier and associated mucous layer play 
an important role in preventing sustained interaction between commensals and immune 
cells. IBD patients commonly have defects in the epithelial barrier which allows for 
commensals to move into the LP and interact with APC and other immune cells. 
Furthermore, bacterial dysbiosis is thought to contribute to disease pathogenesis as IBD 
patients show lower species diversity and other microbial imbalances compared to healthy 
controls 66. Therefore, it is likely that alterations in microbial populations and their 
interactions with immune cells contribute to the development of these conditions. 
 
1.2.4. Intestinal APC hold the key to controlling aberrant immune responses   
 
Due to the central role APC play in linking innate and adaptive immunity, it is possible that 
APC mediate the balance between tolerance and immunity in the intestine. Therefore, 
understanding the composition of intestinal APC populations and the roles individual APC 
populations play in the control of intestinal immunity could provide vital insight into the 
processes that lead to pathologies such as food allergy and IBD. This information could help 
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in the development for therapies for food allergy and IBD by targeting specific cell surface 
molecules or APC subsets. 
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1.3. Intestinal APC 
 
Specialised subsets of APC are found throughout the intestinal lamina propria (LP) and 
associated lymphoid areas including the Peyer’s patches, isolated lymphoid follicles and 
mesenteric lymph nodes (MLN) 100. The intestinal APC population is highly heterogeneous 
consisting of both DC and Mφ 42, 101. Furthermore, the composition of immune cells within 
each compartment is distinct 102, adding an extra layer of complexity to the study of these 
populations. CD11c+ MHCII+ cells from the small intestinal LP are commonly divided into 
two populations, specifically, CD103+ DC and CX3CR1+ Mφ 
42, 101. However, recent 
evidence suggests that these broad populations may contain distinct subsets 103, and may not 
necessarily correspond to DC and Mφ 103.  
 
1.3.1. CD103+ DC 
 
CD103+ DC from the small intestine can be subdivided into two populations based on their 
expression of CD11b and their requirements for development. CD103+ CD11b- DC are 
thought to have a similar phenotype and function to CD103+ CD11b- DC in other tissues 
and CD8α+ DC in lymphoid organs 104. They arise from common DC precursors 101, 105 and 
rely on Flt3L 105 and the transcription factors BatF3 and interferon response element (IRF)-8 
for their development 104. In the intestine, CD103+ CD11b- cells are thought to 
predominantly reside in lymphoid organs such as Peyer’s patches as mice lacking Peyer’s 
patches were shown to have a substantial decrease in the number of CD103+ CD11b- DC 
but unaltered frequencies of other APC populations 101, 106. Small numbers of CD103+ 
CD11b- DC have been reported in LP, however, this appears to be dependent on the 
location within the intestine as CD103+ CD11b- DC have been found to be more abundant 
in distal parts of the small intestine and the colon 102.  In addition to CD103+ CD11b- DC, 
the LP contains a unique population of DC that co-express CD103 and CD11b. Like 
CD103+ CD11b- DC, CD103+ CD11b+ DC arise from common DC precursors but are 
dependent on GM-CSF 105 and the transcription factors Notch2 103, 107 and IRF4 108 for their 
development. Interestingly, Flt3L also appears to play a role in the development of CD103+ 
CD11b+ DC as mice lacking the receptor for Flt3L had reduced numbers of CD103+ 
CD11b+ DC present in the LP compared to wildtype controls 101. Therefore, further 
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investigation is needed to determine the full requirements for the development of steady-
state LP DC. Confocal microscopy studies revealed that CD103+ CD11b+ DC 
preferentially localise deep within the LP to the centre of villi 42, 109 but can be recruited to 
the epithelial barrier during inflammation 72.  
 
Interestingly, there is a lack of evidence showing that CD103+ DC have the capacity to 
directly take up luminal antigen in vivo. Several recent studies suggest that LP DC may 
acquire antigen indirectly. One study proposed that CD103+ DC acquire antigen via gap 
junctions from the CX3CR1+ Mφ population located closer to the epithelium 
56, whereas 
others suggest that goblet cells transfer luminal antigen to DC 110. Despite the lack of 
evidence for antigen uptake, CD103+ have been shown to have migratory capacities. 
Multiphoton confocal microscopy experiments using CD11c-eYFP and CX3CR1-GFP mice 
elegantly demonstrate the presence of CD103+ DC in intestinal lymphatic vessels 42. 
Furthermore, studies tracking the proliferation of APC using BrdU incorporation assays 
show that CD103+ and CD103- cells in the LP incorporate BrdU with faster kinetics than 
CD103+ cells in the MLN. This indicates that the BrdU was incorporated in the LP and the 
cell subsequently migrated to the MLN 109. These studies highlighted the role for CD103+ 
DC in the transport of luminal antigen from the LP to the MLN. In fact, the CCR7 
dependent migration of CD103+ DC 101 has been shown to be vital for the generation of T 
cell responses to orally delivered antigen 55, 111.  
 
Due to the migratory capacity of CD103+ DC, it is likely the CD103+ DC populations 
present in the MLN represent DC derived from the LP. Furthermore, CD103+ DC in the 
MLN were only found in the migratory CD11c+ MHCIIhi population 103. Importantly, 
CD103+ DC from the MLN were capable of presenting orally delivered antigen ex vivo 
whereas CD103- DC populations were not 109 suggesting that CD103+ DC in the transport 
and present luminal antigen in the draining lymph node. 
 
 
1.3.2. CX3CR1+ Mφ 
 
CX3CR1+ cells originate from Ly6C
hi blood monocytes 105, 112, rely on M-CSF for their 
development 101 and are continually replenished from the bone marrow 113. Originally 
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CX3CR1+ cells were classified as DC due to their expression of CD11c, however, evidence 
now supports CX3CR1+ cells are intestinal resident Mφ as they have been shown to express 
Mφ markers F4/80 114, CD64 113 and lack expression of DC specific protein zBTB46 115. 
Furthermore, microscopy studies have shown CX3CR1+ cells to have a vacuolar cytoplasm 
similar to that of Mφ 101. For these reasons, I will be referring to CX3CR1+ cells as Mφ 
throughout this thesis.  
 
At steady-state, CX3CR1+ cells localise to the epithelium 
38, 42, 80. Experiments utilising 
CX3CR1-GFP mice nicely show the presence of transepithelial dendrites in the small 
intestine 75 by which intestinal Mφ sample antigen directly from the lumen 71, 75, 76. 
Furthermore, feeding of fluorescently labelled antigen has been shown to accumulate within 
the CX3CR1+ population 
56, 72. Interestingly, CX3CR1+ cells have not been detected in the 
afferent lymphatics or the MLN which suggests that they do not migrate to the lymph node 
42, although, there is current debate over whether CX3CR1+ cells may gain migratory 
capacity under inflammatory conditions 116. Furthermore, CX3CR1+ cells are poor at 
inducing T cell proliferation 42, 101. Together, these findings suggest that following acquisition 
of antigen, CX3CR1+ Mφ pass antigen onto a migratory DC population. The process by 
which this occurs is not clear, although as discussed above, a recent study demonstrates the 
role of gap junctions in the transfer of antigen between CX3CR1+ and CD103+ populations. 
The study found that MLN DC from mice deficient in Connexin 43, a protein central to gap 
junction formation, were unable to drive T cell proliferation to orally delivered antigen 56. 
This implies that gap junctions are critical for antigen trafficking from the LP to the MLN. 
 
 
1.3.3. Other APC populations 
 
A small population of CX3CR1
int cells has been reported in the LP at steady-state. Similar to 
CX3CR1
hi Mφ, CX3CR1
int cells have been shown to originate from Ly6Chi blood monocytes 
with adoptively transferred Ly6Chi monocytes differentiating into CD11c+ MHCII+ 
CX3CR1
int Ly6Clo cells 99. However, unlike CX3CR1
hi cells, CX3CR1
int cells expand in 
response to Flt3L 42, express lymph node homing receptor CCR7 99,  have been found in the 
intestinal lymph and have some capacity for promoting T cell proliferation 42, 106 suggesting 
they have functional characteristics of DC. Interestingly, during intestinal inflammation, the 
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frequency of CX3CR1
int cells in the LP increases significantly 99, 117 and may promote the 
migration of this population 116. Therefore, it is possible that blood monocytes preferentially 
differentiate into CX3CR1
int cells or CX3CR1
hi Mφ depending on environmental signals. 
 
 
 
 
Figure 1.3: Lineage of intestinal APC 
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Table 1: Summary of cell surface markers expressed by intestinal APC populations 
 
Marker Also known 
as... 
Expressed 
by... 
Function 
CD11b Integrin αM, 
CR3 
Intestinal DC 
and Mφ 
Adhesion molecule 
CD11c Integrin αX Intestinal DC 
and Mφ 
Adhesion molecule commonly used to 
identify DC populations. However, is also 
expressed by intestinal Mφ 42. 
CD64 FcγR1 Monocyte-
derived 
intestinal APC: 
Mφ (moDC?) 
High affinity IgG receptor, although, it is 
unclear how binding of IgG to this 
receptor influences immunity 118. CD64 
clearly distinguishes Mφ from DC in the 
intestine at steady-state 113. 
CD103 Integrin αE Intestinal DC Adhesion molecule 
CX3CR1 Fractalkine 
receptor 
Intestinal Mφ 
(moDC?) 
Chemokine receptor: regulates IL-10 
production and formation of transepithelial 
dendrites by intestinal Mφ  60. 
F4/80 EGF-like 
module 
containing, 
mucin-like 
hormone 
receptor 
Intestinal Mφ  Highly expressed by mature tissue-resident 
Mφ 119, 120 such as those found in the 
intestine. Signalling though F4/80 has been 
associated with the induction of Tregs in 
the periphery 121. 
Ly6C - Monocyte-
derived 
intestinal APC: 
Mφ (moDC?) 
Ly6C on CD8+ T cells is associated with 
regulating T cell proliferation 122, cytolytic 
activity 123 and lymph node homing 124. The 
function of Ly6C on other immune cell 
types is not clear and requires further 
investigation. 
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1.4. APC in the regulation of intestinal immune responses 
 
1.4.1. Intestinal APC and the promotion of tolerance 
 
Migration of antigen-loaded intestinal APC to the MLN is essential for the induction of 
tolerance to the vast amount of foreign antigen 55. This is supported by experiments which 
show that in mice where DC are unable to migration to the MLN 111 or acquire antigen 56, 
were unable to develop tolerance to orally delivered antigen. Interestingly, both CD103+ 
CD11b- and CD103+ CD11b+ DC appear to play a role in promoting tolerance as ablation 
of both of these populations was required to decrease the number of Tregs in the MLN 81. 
In order to maintain tolerance, CD103+ DC are required to simultaneously promote the 
development of Tregs and inhibit the development of effector T cells in the MLN 60, 125. 
Differentiation of naïve T cells to Tregs is promoted by CD103+ DC production of 
chemical mediators such as retinoic acid (RA) and TGF-β 57, 58, 126. CD103+ DC are 
specifically equipped with aldehyde dehydrogenase enzymes, including retinal dehydrogenase 
(RALDH), which are required for the conversion of dietary vitamin A derivatives to RA. In 
addition, CD103+ DC have been shown to produce thymic stromal lymphopoietin (TSLP), 
an epithelial associated cytokine that has been shown to promote the induction of Th2 
responses 24. However, in the intestine, DC derived TSLP may play a role in promoting Treg 
development and inhibiting the development of Th17 cells 127. 
 
In addition to promoting Treg differentiation, RA is required for promoting the upregulation 
of gut-homing receptor α4β7 and gut chemokine receptors CCR9 and CCR10 on T cells 
allowing for them to traffic to the LP and commence their suppressor activities 70, 72, 73. 
Interestingly, mice deficient in components of gut homing molecules or gut homing receptor 
MAdCAM-1 were unable to establish oral tolerance suggesting that gut homing imprinted by 
intestinal DC may also play a role in promoting tolerance 60. Furthermore, intestinal DC play 
an important role in gut imprinting B cells which are required to produce neutralising 
secretory IgA 128, 129. 
 
CX3CR1+ Mφ also play an important role promoting tolerance at steady-state. Primarily, this 
is through production of the anti-inflammatory cytokine IL-10 which helps with the 
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maintenance of FoxP3 expression and suppressive activities by Tregs in the LP 80, 130. Binding 
of fractalkine (CX3CL1) to its receptor CX3CR1 is thought to be important for promoting 
production of specific cytokines 131. Therefore, it is interesting to note that mice deficient in 
CX3CR1 have a significantly lower frequency of IL-10+ intestinal Mφ and subsequently have 
reduced numbers of Tregs in the LP compared to wild-type controls 60. Furthermore, 
CX3CR1 expression was found to be important for establishing oral tolerance as sensitised 
CX3CR1 deficient mice failed to suppress delayed-type hypersensitivity responses following 
oral delivery of antigen 60.  
 
 
 
Figure 1.4: Intestinal APC regulate oral tolerance 
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1.4.2. APC and intestinal immunity 
 
The role of intestinal APC in the promotion of tolerance is relatively well understood. 
However, the mechanisms by which intestinal APC identify threats and initiate effector T 
cell responses is less well defined. Furthermore, it is unclear whether specific subsets within 
characterised APC populations are responsible for driving different immune responses or 
whether environmental signals condition APC to drive appropriate effector T cell responses.  
 
Th1 responses are characteristic of bacterial, protozoan and viral infections 73, 108, 132, 133 but 
have also been implicated in IBD pathology 95. A subset of intestinal CD103+ CD11b- 
CD8α+ DC have been implicated in promoting Th1 responses in response to TLR 
stimulation. This subset was found to produce IL-6 and IL-12 and drive IFNγ but not IL-17 
production by antigen specific CD4 T cells in vitro and in vivo when exposed to TLR agonists 
73. Similar experiments showed that CD103+ CD11b+ DC also drove Th1 differentiation in 
response to TLR ligands 133. Furthermore, a subset of CX3CR1
int cells has been associated 
with inflammatory Th1 responses in mouse models of colitis. Studies have shown during 
colonic inflammation there is a transient increase in CX3CR1
int cells that have a pro-
inflammatory transcriptomic signature and produce large amounts of pro-inflammatory 
cytokines 117, 134, 135. Ablation of the CX3CR1
int subset significantly reduced colonic 
inflammation, further implicating this subset in driving effector T cell responses 99. The roles 
of intestinal monocytes and Mφ have also been assessed and were found to provide cytokine 
help to established Th1 immune responses but were not required for T cell priming. 
Furthermore, monocytes and Mφ from the small intestine produce IL-12 in instances of 
inflammation and thus, contribute to T cell IFNγ responses 136.  
 
In addition to driving Th1 responses, CD103+ CD11b+ DC have been specifically 
implicated in driving Th17 80, 81, 102, 133, 137  and IL-22/IL-23 63 effector responses in the 
intestine. Studies have shown CD103+ CD11b+ DC promote Th17 differentiation without 
stimulation in vitro, however, Th17 differentiation was enhanced following stimulation with a 
TLR5 agonist 80, 102, 133. The involvement of CD103+ CD11b+ DC in Th17 cell homeostasis 
was further supported by experiments showing that conditional depletion of CD103+ 
CD11b+ DC resulted in a significant decrease in Th17 cells in the MLN 81. Moreover, 
specific deletion of Notch2 in CD11c+ cells has been shown to effectively reduce the 
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numbers of CD103+ CD11b+ DC in the intestine without affecting other APC populations. 
These mice succumbed to infection with the bacteria Citrobacter rodentium whereas BatF3 
knockout mice, deficient in CD103+ CD11b- DC, and wildtype mice effectively cleared 
infection. The inability for Notch2 deficient DC to promote infection clearance was ascribed 
to their inability produce the cytokine IL-23 103 which is important for promoting 
antimicrobial activities by other immune cells and epithelial cells (see Section 1.2.2) 138. 
 
The specific requirements to drive Th2 responses in the intestine and other tissues have 
been the focus of much study and review 1, 139, 140, 141, 142. However, the APC subsets and 
mechanisms involved in the promotion Th2 immunity are not known. Studies in helminth 
infection models have reported changes in MLN DC composition, notably, an increase in 
CD11clo CD103- DC 143, although the relevance of this finding is unclear. Current evidence 
suggests environmental signals may alter expression of cell surface markers on APC that 
promote Th2 differentiation 24. In the intestine, expression of a number of “Th2 skewing” 
markers, including  OX40 ligand (OX40L) 86 and T cell immunoglobulin and mucin domain 
containing-protein (TIM)-4 144, on CD103+ DC has been associated with the development 
of Th2 immunity in mouse models of food allergy. TIM-4 is predominantly expressed on 
Mφ populations 145, 146 but has been shown to be upregulated on DC stimulated with TLR 
ligands 147, 148. DC expressing TIM-4 were found to promote Th2 differentiation in vitro and in 
vivo 144, 147, 149 and blockade of TIM-4 or, one of its target receptors, TIM-1 prevented Th2 
differentiation and allergic anaphylaxis thus implicating Th2 promotion via signalling 
through the TIM-4/TIM-1 interaction 144. 
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1.5. Cholera toxin: a potent mucosal adjuvant 
 
Cholera toxin (CT) is a potent mucosal adjuvant that is produced by the bacterium Vibrio 
cholera and consists of two subunits, a monomeric A subunit and a pentameric B subunit. CT 
is known to exert its pathogenic effects on intestinal epithelial cells through binding of CT-B 
to cell surface GM-1 ganglioside receptors which facilitates entry of CT-A into the cell. Once 
inside the cell, CT-A causes the continual activation of adenylate cyclase by influencing G-
protein activation which results in efflux of water and electrolytes and ultimately, global 
cellular dysregulation 150, 151, 152, 153. 
 
In addition to its pathological effects on epithelial cells, CT is also known to promote 
effector T cell responses to co-delivered antigen and thus is commonly used as an adjuvant 
at mucosal sites. Interestingly, CT has been reported to preferentially induce Th2 responses 
150, 154, 155, 156, although, others claim CT has general stimulatory effects on immune cells 
driving Th1 and Th2 responses simultaneously 151, 157, 158, 159. To induce its immunostimulatory 
effects, CT primarily affects the phenotype and function of APC 86, 144, 153, 158, 159, 160, 161. 
Experiments using bone marrow chimeric mice deficient in GM1 expression on 
haematopoietic cells, show that direct interaction between CT and DC was required for 
adjuvant activity. This was further confirmed using CD11c-DTR GM1-/- mixed bone 
marrow chimeric mice. DT depletion in these mice failed to induce antigen specific T cell 
proliferation following an oral dose of antigen with CT 160. In addition, CT has been 
investigated as a potential vaccine adjuvant. Co-administration of CT with antigen resulted in 
dermal DC activation, migration and induction of potent CD8 T cell responses 159. 
 
The ability of CT to induce potent T cell responses to co-delivered antigen and promote 
epithelial cell dysfunction allowing for increase antigen availability, makes it a useful tool to 
study the effect of an immunostimulatory agent on intestinal immune cells. Due to its Th2 
skewing properties, CT is already commonly used to sensitise mice to orally co-delivered 
antigen in models of food allergy 162. Therefore, I used oral CT treatment to study the 
phenotype and functions of intestinal APC subsets in an environment in which effector T 
cell responses were initiated. 
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1.6. Rationale and hypothesis 
 
APC are the gatekeepers to adaptive immunity. They have the capacity to acquire antigen 
and direct the appropriate T cell responses. Due to the high antigenic load at mucosal sites, 
intestinal APC are specialised to induce tolerance at steady-state but remain capable of 
inducing potent immune responses to pathogens. Inappropriate immune activation is 
associated with a number of pathologies including food allergy and inflammatory bowel 
disease. The mechanisms by which APC drive intestinal immune responses in infection and 
pathology is currently unknown. I used the mucosal adjuvant CT to induce an environment 
in which effector immune responses were initiated in order to study intestinal APC. As 
signals from APC direct T cell proliferation and differentiation, I hypothesised that CT 
treatment would alter the phenotype and function of some APC in the LP and MLN and 
that these APC would be responsible for the generation of effector T cell responses to CT.  
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1.7. Aims of this thesis 
 
In this chapter I have highlighted the key roles APC have in the initiation and direction of 
adaptive immune responses. Regulation of adaptive immune responses is particularly 
important in the intestine where APC are constantly exposed to microbial agents and foreign 
antigen. At steady-state intestinal APC drive tolerance through the promotion of Treg 
differentiation and production of the anti-inflammatory cytokine IL-10. However, intestinal 
APC retain the capacity to induce appropriate immune responses to pathogens or 
inappropriate immune responses to food proteins and commensal bacteria. The mechanisms 
that determine APC promotion of either Tregs or effector T cell differentiation remain 
elusive. Oral administration of the mucosal adjuvant CT can provide a useful setting to study 
APC in an immunostimulatory environment. Therefore, the overall aim of this study was to 
compare APC subset composition, phenotype and function between steady-state and 
following oral administration of CT. 
 
Specifically my aims were: 
 
1. To assess the APC subset composition and phenotype from the LP and MLN at 
steady-state.  
 
2. To identify whether CT treatment alters LP and MLN APC subset composition and 
phenotype. 
 
3. To assess and compare functional characteristics of APC subsets between steady-
state and CT treatment. 
 
4. To characterise T cell expansion and cytokine production following oral 
administration of CT. 
 
 
 Chapter 2: Materials and 
Methods 
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2.1. Materials 
 
2.1.1. Labware 
 
Product Supplier 
Acrodisc® 32 mm syringe filter with 0.2μm Supor® 
membrane 
PALL Life Sciences (Cornwall, UK) 
Axygen® sterile pipet tips 1000, 200 & 10 μL Axygen Scientific Inc. (Union City, CA, 
USA) 
Falcon 1, 3, 5, 10 mL Tuberculin syringes Becton Dickinson (BD) Biosciences 
(Bedford, MA, USA) Falcon polystyrene sterile conical tubes: Blue Max 
50 mL and Blue Max Jr. 15 mL 
Falcon polystyrene sterile multiwall tissue culture 
plates: 6 well, 12 well, 24 well, 48 well and 
MicrotestTM Ubottom 96 well plates 
Falcon 2, 5, 10 and 25mL Polystyrene serological 
pipettes 
Falcon Nylon cell strainers: 40μm and 70μm 
Falcon 5mL polystyrene round bottom tubes 
PrecisionGlideTM needles: 18, 25 gauge (G) 
Ultra-FineTM needle insulin syringes: 29 gauge 0.3, 
0.5 & 1 mL 
Disposable Biopsy Punch (3mm diameter) Kai Industries (Seki City, Japan) 
Gavage needles: 22G, 1.5” stainless steel Cadence Science (Staunton, VA, USA) 
MACS® AutoMACS separation columns Miltenyi Biotech GmbH (Bergisch 
Gladbach, Germany) MACS® pre-separation filters, 30μm 
Carbon Steel Surgical Blades number 10 & 22 (sterile) Swann-Morton® Limited  (Sheffield, 
England) 
Titertube® Micro Tubes Bio-Rad (Hercules, CA, USA) 
Nunc-Immuno™ MicroWell™ 96 well solid plates Sigma-Aldrich (St. Louis, MO, USA) 
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2.1.2. Reagents 
 
Product Supplier 
2-mercapto-ethanol (2-ME) 55 mM solution Sigma-Aldrich (St. Louis, MO, USA) 
ALDEFLUOR kit (Aldehyde Dehygrogenase – 
based cell detection kit) 
Stem Cell Technologies (Victoria, 
Australia) 
Ammonium chloride powder Sigma-Aldrich (St. Louis, MO, USA) 
Ampicillin  
Annexin-V Apoptosis Detection Kit II BD Pharmingen (San Diego, CA, USA) 
Bovine serum albumin (BSA), lyophilised powder ICPbio Ltd. (Auckland, NZ) 
Brefeldin A solution eBioscience (San Diego, CA, USA) 
Cholera toxin, lyophilised powder Sigma-Aldrich (St. Louis, MO, USA) 
Cytofix/Cytoperm kit BD Pharmingen (San Diego, CA, USA) 
Dexamethasone – water soluble Sigma-Aldrich (St. Louis, MO, USA) 
Dextran sulfate sodium (DSS) salt MP Biomedicals (Solon, OH, USA) 
DNase I powder Roche (Mannheim, Germany) 
Dynabeads®, FlowComp™ Mouse CD4 Invitrogen (Auckland, New Zealand) 
Ethanol, 100% Carlo Erba Reagents (Milan, Italy) 
Ethylenediaminetetraacetic acid (EDTA) 
powder 
Sigma-Aldrich (St. Louis, MO, USA) 
Fetal calf serum (FCS) Invitrogen (Auckland, New Zealand) 
Gentamicin sulfate Sigma-Aldrich (St. Louis, MO, USA) 
Goat serum 
GolgiStop BD Pharmingen (San Diego, CA, USA) 
Hank’s Balanced Salt Solution (HBSS) supplemented 
with calcium chloride and magnesium chloride 
Invitrogen (Auckland, New Zealand) 
Hepes buffer 1M solution Sigma-Aldrich (St. Louis, MO, USA) 
Iscove’s Modified Dulbecco Medium 
(IMDM) supplemented with GlutaMAX TM, 
25 mM HEPES buffer and 3.024 mg/L 
NaHCO3 
Invitrogen (Auckland, New Zealand) 
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Liberase TL powder Roche (Mannheim, Germany) 
Interleukin (IL)-2 IL-2 producing IL2L6 cell line, generated 
by the modification of murine J558 
parental line 
Magnetic separation (MACS) beads, anti-CD11c 
microbeads 
Miltenyi Biotech GmbH (Bergisch 
Gladbach, Germany) 
Metronidazole Sigma-Aldrich (St. Louis, MO, USA) 
Neomycin trisulfate salt hydrate Sigma-Aldrich (St. Louis, MO, USA) 
Neurotactin (NTN), CX3CL1- human Fc fusion 
protein 
Kindly provided by Prof. Steffen Jung 
(Weizmann Institute of Science, Rehovot, 
Israel) 
Ovalbumin (OVA) grade V protein powder Sigma-Aldrich (St. Louis, MO, USA) 
OVA323-339 (ISQAVHAAHAEINEAGR) 
Peptide (ISQ) 
Mimotopes (Victoria, Australia) 
OVA conjugated to AlexaFluor-647 Molecular Probes® (Eugene, Oregon, 
USA) 
Penicillin-streptomycin Invitrogen (Auckland, New Zealand) 
Phosphate buffer saline (PBS) Invitrogen (Auckland, New Zealand) 
Proliferation dye eFluor-670 eBioscience (San Diego, CA, USA) 
Sodium azide powder Sigma-Aldrich (St. Louis, MO, USA) 
Sodium chloride (NaCl) BDH Laboratory Supplies (Poole, 
England) 
Tris powder Invitrogen (Auckland, New Zealand) 
Vancomycin hydrochloride hydrate Sigma-Aldrich (St. Louis, MO, USA) 
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2.1.3. Buffer and solution compositions 
 
Antibiotic cocktail (Abx) 1mg/mL ampicillin         
1mg/mL gentamicin        
1mg/mL metronidazole      
1mg/mL neomycin         
0.5mg/mL vancomycin       
sterile distilled H2O 
Ammonium chloride Tris (ACT) buffer 0.144M Ammonium chloride pH 7.4 
17mM Tris pH 7.4 
AutoMACS rinsing buffer 2mM EDTA 
PBS 
AutoMACS running buffer 2mM EDTA 
1% FCS 
PBS 
Bicarbonate buffer, pH 9.6 0.1M Na2CO3 
0.1M NaHCO3 
Complete media (cIMDM) 1% Penicillin-streptomycin 
55μM 2-ME 
5% FCS 
IMDM 
Digestion solution for gut samples 57.5g/mL liberase TL  
IMDM 
Digestion solution for lymph node samples 100g/mL liberase TL 
100g/mL DNase I 
IMDM 
Fluorescent activated cell sorting (FACS) buffer 10mM EDTA pH 8.0 
0.01% NaN3 
2% FCS 
PBS 
Isolation buffer 0.1% w/v BSA 
2mM EDTA 
25g/mL DNase I 
PBS 
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Stripping buffer 2mM EDTA 
25mM Hepes buffer 
10% FCS 
HBSS 
 
2.1.4. Antibodies 
 
Antibodies were purchased from BD Biosciences including BD Pharmingen™ and BD 
Horizon™ (San Diego, CA, USA), BioLegend (San Diego, CA, USA), eBioscience (San 
Diego, CA, USA), and R&D Systems (Minneapolis, MN, USA) or purified and conjugated 
in-house. 
 
2.1.4.1. Flow cytometry 
All antibodies were titrated and the optimal dilution was determined. Before each use, 
antibodies were spun down to avoid adding antibody aggregates to samples. Antibody 
cocktails were made up in FACS buffer with appropriate dilutions and stored in the dark on 
ice until use. 
 
Antibody specificity Conjugates Clone Supplier 
47 (LPAM-1) PE DATK32 BioLegend 
CCR7 APC 4B12 BioLegend 
CCR9 FITC 242503 R&D Systems 
CD4 FITC GK1.5 BD Pharmingen 
CD4 Pacific Blue RM4-5 BD Pharmingen 
CD11b AF700, PerCPCy5.5 M1/70 BioLegend 
CD11c PECy7 HL3 BD Pharmingen 
CD44 APC-eFluor780 IM7 eBioscience 
CD45  AmCyan 2D1 BD Biosciences 
CD45R (B220) FITC 6B2 In-house 
CD45.1 PECF594 A20 BD Horizon 
CD45.2 APC, APC-eFluor780 104 Biolegend, 
eBioscience 
CD64 APC, PerCPCy5.5 X54-5/7.1 Biolegend 
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CD69 PerCPCy5.5 H1.2F3 Biolegend 
CD86 FITC GL-1 BD Pharmingen 
CD103 Biotin, PE M290 BD Pharmingen 
CXCR5 Biotin 2G8 BD Pharmingen 
FcγRII/III (Fc Block) - 2.4G2 In-house 
F4/80 PE BM-8 eBioscience 
IFNγ APC XMG1.2 BD Pharmingen 
IL-4 PECy7 11B11 Biolegend 
IL-17A FITC TC11-18H10.1 Biolegend 
Isotype IgG1 (F(ab’)2 goat 
anti-human) 
APC - Jackson 
ImmunoResearch 
Laboratories (PA, 
USA)  
Isotype IgG2a Biotin R35-95 BD Pharmingen 
Isotype IgG2b APC 27-35 BD Pharmingen 
MHCII AF647, FITC 3JP In-house 
MHCII APC-Cy7 I-A/I-E BioLegend 
OX40L Biotin RM134L eBioscience 
Streptavidin  PE Texas-Red Streptavidin BD Pharmingen 
TIM-4 AF647, PE RMT4-54 BioLegend 
V2 APC B20.1 eBioscience 
Vβ5.1/5.2 PE MR9-4 BD Pharmingen 
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2.1.5. Viability dyes 
 
4,6-diamidino-2-phenylindole, dihydrochloride (DAPI) was purchased from Invitrogen 
(Auckland, New Zealand) and a working stock was prepared in FACS buffer at a 
concentration of 5mg/mL. DAPI was added to samples at a dilution of 1:25,000 just before 
analysis. 
 
7-Amino-Actinomycin D (7-AAD) was purchased from BD Pharmingen (San Diego, CA, 
USA). A 1:80 dilution was added to samples just before analysis. 
 
Live/dead fixable blue was purchased from BD Pharmingen (San Diego, CA, USA). Prior to 
use, dye was reconstituted in DMSO. A 1:200 dilution was added to samples. Staining was 
performed as per manufacturer’s instructions. 
 
Propidium Iodide (PI) was purchased from BD Pharmingen (San Diego, CA, USA). A 1:200 
dilution was added to samples just before analysis. 
 
2.1.6. Mice 
 
Maintenance and ethical approval 
Mice were bred and housed at the Malaghan Institute of Medical Research Biomedical 
Research Unit in Wellington, New Zealand. Sex matched mice of 6-8 weeks of age were 
used for all experiments. All protocols were approved by the Victoria University of 
Wellington Animal Ethics Committee. Protocol reference: 2012R4M 
 
Mouse strains 
 
C57BL/6J (C57) Breeding pairs were originally obtained from The Jackson Laboratory (Bar Harbour, 
ME, USA). 
 
4C13R mice express the fluorescent reporters AmCyan and DS-Red for the cytokines IL-4 
and IL-13 respectively. These mice were created using a bacterial artificial chromosome 
(BAC) clone spanning the il4 and il13 coding and regulatory regions. Reporter constructs 
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were inserted into the appropriate regions of BACs by homologous recombination 163. To 
check mice had inherited the reporter construct, all mice were tested by isolating DNA from 
tail samples and using PCR to target the DS-Red coding sequence. 4C13R mice were obtained 
from Dr. William E. Paul (National Institute of Allergic Diseases, National Institutes of Health, MD, 
USA). 
 
B6-SLJ ptprca (CD45 congenic) mice express CD45.1 antigen on lymphocytes which can 
be differentiated from lymphocytes from a C57BL/6 (CD45.2) background. Breeding pairs 
were originally obtained from the Animal Resources Centre (Canning Vale, WA, Australia).  
 
Toll-like receptor 4 knockout (TLR4-/-) mice are deficient for TLR4 and have been bred 
onto a C57 background 164. Breeding pairs were obtained from the Research Institute of Microbial 
Diseases (Osaka University, Japan). 
 
OTII mice express a transgenic CD4 T cell receptor specific for the MHCII restricted 
OVA323-339 peptide 
165. Mice were tail bled and tested for the transgenic receptor V2 and V 
5.1/5. by flow cytometry. OTII mice were obtained from Dr Sarah Hook (University of Otago, 
Dunedin, New Zealand). 
 
OTII x B6-SJL ptprca and OTII x 4C13R OT-II B6-SJL ptprca and OT-II 4C13R mice 
were obtained by crossing OTII mice with B6-SJL ptprca for one generation or with 4C13R 
mice for one generation at the Malaghan Institute of Medical Research BRU facility. OTII 
B6-SLJ ptprca mice were tested for inheritance of the transgenic receptor V2 and V 
5.1/5. by flow cytometry. In addition to being tested for inheritance of the transgenic T cell 
receptor, OT-II 4C13R were tested for inheritance of the reporter construct by PCR 
targeting the DS-Red coding sequence. 
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2.2. Methods 
 
2.2.1. Mouse manipulations  
 
2.2.1.1. Intragastric (i.g.) administration 
Solutions were administered to mice in a volume of 200-250µL via oral gavage using a 22G 
gavage feeding needle. 
 
Intragastric administration of antigen 
Mice were given 50mg OVA or BSA in a volume of 250μL in bicarbonate buffer via oral 
gavage. 
 
To track OVA protein following i.g. administration, mice were given 250g fluorescently 
labelled OVA (OVA-AF647) in a volume of 250L in bicarbonate buffer via oral gavage . 
 
Intragastric administration of cholera toxin 
Mice were gavage fed 10g of cholera toxin in 250L bicarbonate buffer via oral gavage. 
 
Intragastric administration of antibiotics 
An antibiotic cocktail of 1mg/mL ampicillin, gentamycin, metronidazole, neomycin and 
0.5mg/mL vancomycin was administered by oral gavage in 200μL sterile H2O. 
 
Intragastric administration of dextran sulfate sodium (DSS) 
DSS was administered in the drinking water at 2.5%w/v for 3-5 days.  
 
2.2.1.2. Intravenous (i.v.) injection 
Injections were carried out with a 29G insulin needle into the lateral tail vein of restrained 
mice. 
 
Injection of CD4+ OTII cells 
To assess T cell responses following CT treatment, 5x106 splenic CD4+ OTII cells enriched 
by Dynabead selection (section 2.2.3.2) were injected in 200µL IMDM.  
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Injection of Brefeldin A 
In vivo cytokine production by T cells can be measured directly ex vivo using brefeldin A, 
which prevents cytokine secretion and allows for the detection of cytokine stored inside the 
cell. Mice were injected with 250µg brefeldin A in PBS in 250µL and sacrificed 4 hours later. 
 
2.2.1.3. Euthanasia 
Mice were euthanised by CO2 asphyxiation or cervical dislocation. 
 
 
2.2.2. Tissue harvest and processing 
 
2.2.2.1. Lymph nodes 
Inguinal, axillary, cervical and mesenteric (MLN) lymph nodes were removed from 
euthanised mice. Excess tissue was carefully removed and the lymph nodes were placed in 
IMDM. 
 
OTII cell isolation from lymph nodes 
Isolated lymph nodes from OTII x B6-SJ ptprca mice were flushed through a 70m cell 
strainer using the rubber end of a syringe. The strainer was washed twice with 5mL cIMDM. 
The samples were centrifuged for 10 minutes at 250xg, supernatant discarded and the pellet 
disrupted by flicking. Cells were resuspended in 10mL cIMDM prior to CD4 Dynabead 
enrichment (section 2.2.3.2).  
 
Dendritic cell isolation from mesenteric lymph nodes 
Isolated MLN were broken up with a 25G needle in 1mL of Liberase TL (100µg/mL) and 
DNase (100µg/mL) digest solution and incubated for 25 minutes at 37C. In the last 5 
minutes of incubation EDTA was added at a final concentration of 10mM . Cell were 
collected and filtered through a 70m nylon cell strainer, centrifuged at 250xg and 
resuspended in 200μL IMDM. 
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2.2.2.2. Jejunum 
To isolate the jejunum, the small intestine was cut at 1.5 cm from the base of the stomach 
and the first 8cm from the top of the section was collected for lamina propria isolation. The 
section was flushed with 10mL of HBSS using an 18G needle and lightly pressed with 
forceps to remove intestinal waste, and excess mesenteric tissue and Peyer’s patches were 
excised. The gut section was cut longitudinally and vigorously shaken in a 6 well plate with 
HBSS to remove mucus. 
 
Lymphocyte isolation from lamina propria 
To remove the epithelial cell layer, sections were placed in 5mL pre-warmed stripping buffer 
(2.1.3) and vigorously vortexed before being incubated at 150rpm for 15 minutes at 37°C in 
a shaking incubator (Edison, NJ, USA). Following incubation, the samples were vortexed 
and transferred to a new tube with 5mL pre-warmed stripping buffer and the process 
repeated. Samples were then rinsed in IMDM and transferred to a 6 well culture plate. 
Samples were finely chopped and 5mL of pre warmed liberase TL digest solution was added 
to each sample at 57.5µg/mL. Tissue was disrupted using a 3mL syringe and incubated at 
37C at 100rpm for 1 hour. To removed cell clumps, samples were filtered through a 40m 
nylon filter prior to washing with IMDM. The cell pellet was resuspended in 200L IMDM. 
 
2.2.2.3. Spleen 
Spleens were removed and kept on ice in IMDM until processing. Single cell suspensions 
were prepared by pressing spleens through a 70m cell strainer with the end of a syringe and 
washed through with 20mL IMDM. The cells were pelleted by centrifuging at 250xg for 10 
minutes and the supernatant discarded. Cells were then incubated with 5mL of ACT lysis 
buffer at 37C to lyse red blood cells and washed with IMDM. The pellet was resuspended 
in 10mL IMDM and an aliquot taken for counting.  
 
2.2.2.4. Thymus 
The thymus was removed from 4-5 week old mice and a single cell suspension was made by 
pressing the thymus through a 70μM cell strainer with the base of a syringe. Cells were 
washed through the cell strainer with 10mL IMDM.  
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Labelling of thymocytes with eFluor670 dye 
Thymocytes were resuspended at 4x106 cells/mL in PBS pre-warmed to 37°C and equal 
volume of 10μM eFluor670 in pre-warmed PBS was added to cell suspension while 
vortexing. Cells were incubated in the dark for 10 minutes at 37°C to incorporate the dye. 
The labelling reaction was stopped by adding 3x volume 100% FCS and incubating on ice 
for 5 minutes. Cells were subsequently washed thrice with IMDM to remove any excess dye. 
 
Inducing apoptosis in thymocytes 
Thymocytes were incubated in 3mL 10μM dexamethasone solution for 4 hours at room 
temperature. Apoptosis was confirmed by Annexin-V and PI staining. 
 
2.2.2.5. Counting of viable cells 
Cells were counted by trypan blue exclusion. Aliquots of single cell suspensions were diluted 
at 1:2 or 1:10 in Trypan Blue dye. 10µL of diluted cells were applied to a haemocytometer 
and the number of live cells was counted under a light microscope. Cells that excluded the 
dye were counted as viable. 
 
 
2.2.3. Cell purification 
 
2.2.3.1. Magnetic cell separation (MACS) 
Cells were suspended at 2.5x108 cells/mL in AutoMACS running buffer and filtered through 
40μm cell strainer. MACS microbeads were added to the cell suspension at the appropriate 
dilution and incubated at 4°C for 15 minutes. Cells were washed with 2mL AutoMACS 
running buffer and centrifuged at 250xg for 10 minutes. Cells were resuspended in 500μL 
AutoMACS running buffer and filtered through a 30μM MACS pre-separation filter before 
proceeding to magnetic separation on the AutoMACS machine (Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany). 
 
2.2.3.2. Dynabead purification 
Cells were resuspended at 1x108 cells/mL in isolation buffer. 10uL of antibody per 1 x 107 
cells was added and the sample and incubated for 10 minutes on ice. Cells were then washed 
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and resuspended at 5x107 cells/mL in isolation buffer. FlowComp™ dynabeads were added 
to the cell suspension, mixed well and incubated for 15 minutes at 4°C with continuous 
agitation. Following incubation, samples were placed in an Invitrogen DynaMag™ for 1 
minute at room temperature and the supernatant was carefully removed and discarded. The 
cells and bound beads were resuspended in 1mL isolation buffer and the process repeated. 
To remove the bound beads, cells were incubated with 1mL FlowComp™ release buffer for 
15 minutes at room temperature rolling and tilting. To remove the unbound beads, sample 
tubes were place in the DynaMag™ and the supernatant was transferred to a new tube. Cells 
were spun down and resuspended in cIMDM. 
 
 
2.2.4. Cell staining 
 
2.2.4.1. Cell surface staining 
5x105-5x106 cells/well were plated out onto a 96 well round bottom plate. Cells were 
resuspended in 100µL of Fc Block (2.4G2) and incubated for 10 minutes at 4°C and then 
centrifuged at 250xg for 2 minutes and supernatant discarded. Fluorecently labelled antibody 
cocktails were prepared using predetermined dilutions and 100µL of mixture was added to 
cells followed by incubation at 4°C for 20 minutes before being washed twice with 100µL 
FACS buffer . For secondary antibody staining, cells were incubated at 4ºC for a further 20 
minutes with the diluted antibody and washed twice with FACS buffer. After the final wash, 
samples were resuspended in 200µL FACS buffer containing viability dye (section 2.2.4.3.) 
and transferred to microtubes for immediate flow cytometric analysis.  
 
Cell surface staining of CX3CR1 
To stain cell surface CX3CR1, cells were plated out into 96 well plates and blocked with 
100μL 10% goat serum for 30 minutes at 4°C. Cells were spun down and resuspended in 
50μL CX3CR1-Fc fusion protein NTN and incubated for 30 minutes at 4°C. Cells were 
washed twice with cold FACS buffer and resuspended in 50μL of the secondary antibody, 
goat anti-human IgG1-APC. and incubated for a further 30 minutes at 4°C, cells were 
washed twice with cold FACS buffer and stained for other cell surface antigens. 
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2.2.4.2. Intracellular cytokine staining 
Cells isolated from brefeldin A-treated mice were stained with live/dead fixable blue (section 
2.2.4.3.) and cell surface markers (section 2.2.4.1.). Cells were then assessed for intracellular 
cytokines with a BD Cytofix/Cytoperm™ kit following the manufacturer’s protocol. Briefly, 
cells were fixed in cytofix/cytoperm solution for 20 minutes at 4ºC, and then washed twice 
with Perm/Wash™ buffer. Antibodies targeting cytokines were diluted in Perm/Wash™ 
buffer and added to cells for 30 minutes at 4ºC. Cells were washed thrice and resuspended in 
FACS buffer prior to flow cytometric analysis. 
 
2.2.4.3. Detection of retinal dehygrogenase with ALDEFLUOR kit 
To assess retinal dehydrogenase (RALDH) activity, cells were stained for ALDEFLUOR, a 
lipid soluble substrate the fluroesces upon interaction with aldehyde dehydrogenases. 1μL 
activated ALDEFLUOR was added to the cell suspension and mixed well. To prepare a 
negative staining control an aliqout of sample was removed and 5L of the specific aldehyde 
dehydrogenase inhibitor diethylaminobenzaldehyde (DEAB) was immediately added to 
control samples. Cells  were incubated for 20 minutes at 37°C to allow for the reaction to 
take place. Following incubation, cells were pelleted at 250xg for 5 minutes. Cell were then 
stained with antibodies against cell surface antigens (section 2.2.4.1.) which was carried out 
in  ALDEFLUOR assay buffer to prevent ALDEFLUOR efflux. 
 
2.2.4.4. Viability dye staining 
Just prior to flow cytometic analysis DAPI or 7-AAD or PI was added to stained samples in 
FACS buffer at the appropriate dilution (section 2.1.5.) 
 
Fixable viability dye staining 
Fixable viability dyes were added to cell suspension at the appropriate dilution in FACS 
buffer. Cells were incubated at 4ºC for 30 minutes and washed prior to cell surface staining. 
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2.2.5. Flow cytometry 
 
2.2.5.1. Controls 
Unstained cells, single stained compensation beads and fluorescence minus one (FMO) 
stained cells were used as controls for all experiments. Isotype antibody staining controls 
were used when necessary to control for background fluorescence.  
 
2.2.5.2. Acquisition and analysis of data 
Samples were filtered through a 40µm cell strainer and run on a LSRFortessa™ or a LSR II 
flow cytometer (BD Biosciences, San Jose, CA, USA) using FACS Diva software. A 
minimum of 1x106 events were collected for jejunal samples and a minimum of 2.5x106 
events were collected for MLN samples. Flow rate was maintained below 5000 events per 
second. 
 
Following acquisition, all data was analysed using FlowJo software (version 9.7). Doublets 
gated out using forward and side scatter parameters and dead cells excluded as indicated by 
viability dye staining prior to any additional analysis. Full gating strategies can be found in 
Appendix I and II. 
 
 
2.2.6. Assays of cell function 
 
2.2.6.1. In vitro phagocytosis assay 
Purified CD11c+ cells from the LP or MLN were incubated for 1 hour at 37°C with e670 
labelled or unlabelled apoptotic thymocytes at a ratio of 1:10. Following incubation, cells 
were harvested and stained for analysis by flow cytometry. Phagocytic ability was determined 
by e670 incorporation by CD11c+ cell subsets. 
 
 
2.2.7. Statistical analysis 
 
Data was analysed using Prism software and means±standard error of the mean are 
displayed on bar graphs. P-values of <0.05 from a Student’s unpaired t-test, One-Way 
ANOVA test or Two-Way ANOVA test were classified as being statistically significant.  
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3.1. Introduction  
 
APC in the intestine are exposed to vast amounts of foreign antigen and play an important 
role in the prevention of inappropriate immune responses to food proteins and commensal 
bacteria 42, 55, 111. For this reason, intestinal APC differ from those found in other tissues and 
common markers used to define APC populations may not be applicable in the intestine. 
Interestingly, despite the importance of intestinal APC in maintaining immune homeostasis, 
there are still many unanswered questions about the composition and functions of the highly 
heterogeneous intestinal APC population at steady-state. 
 
Intestinal APC, identified by co-expression of CD11c and MHCII, are commonly classified 
into two broad populations based on their expression of the non-overlapping markers 
CD103 and CX3CR1 (see Section 1.3) 
42, 101. However, there is increasing evidence that this 
classification fails to highlight the highly heterogeneous nature of intestinal APC 
populations. While co-expression of CD11c and MHCII is  useful in identifying DC 
populations in other tissues 37, CD11c+ MHCII+ cells from the intestine consist of a 
mixture of DC and Mφ 101, 105. CD103+ cells are phenotypically similar to DC 42, whereas, 
CX3CR1+ cells are usually considered to be closely related to Mφ 
101, 105 due to their 
expression of the Mφ markers F4/80 114 and CD64 113, lack of expression of the DC specific 
protein zBTB46 115 and the presence of vacuoles in their cytoplasm 101. However, recent 
studies using GFP-reporter mice have shown a proportion of CX3CR1+ cells express DC 
specific protein zBTB46, suggesting that the classification of all of these cells as Mφ may not 
be appropriate 103. Furthermore, there are subsets of CD11b+ and CD11b- cells within the 
CD103 and CX3CR1 populations 
101 (see Section 1.3.) and there is a population of CD11c+ 
MHCII+ cells that lack expression of both CD103 and CX3CR1. Understanding 
composition of intestinal APC subsets is further complicated by the fact that different labs 
use different mouse strains 75, 166 and use various intestinal processing protocols, which may 
or may not exclude Peyer’s patches 101, for their studies. In addition, sections of the intestine 
have very distinct APC compositions, therefore, study of different intestinal sections may 
yield very different results 80. Therefore, due to the discordance among published studies in 
relation to the composition of intestinal APC and the underappreciated heterogeneity of 
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APC populations, I sought to develop an improved strategy of characterising jejunal APC to 
gain a clear understanding of the subsets present at steady-state.  
 
In addition to APC phenotype and subset composition, I was interested in assessing some 
functional aspects of intestinal APC populations at steady-state. In order to initiate T cell 
responses, APC are required to take up antigen in the tissue and migrate to the draining 
lymph node where they can present antigen to T cells 9. While these processes are well 
understood in other tissues, they remain an enigma in the intestine. This is because 
CX3CR1+ cells localise to the epithelial barrier 
38, 42, 80 where they are thought to be 
responsible for the uptake of luminal antigen through transepithelial dendrites 71, 75, 76. 
However, CX3CR1+ cells are non-migratory and poor at inducing T cell proliferation 
42, 101. 
On the other hand, CD103+ cells preferentially localise to the centre of villi and experiments 
have failed to demonstrate that CD103+ DC have the capacity to take up antigen in vivo. 
Nevertheless, CD103+ DC migrate to the MLN in a CCR7 dependent manner 111 and are 
potent drivers of T cell proliferation to orally delivered antigen 101, 108. Thus, a unique 
situation appears to exist in the intestine where antigen transfer may be required to take 
place between the CX3CR1 and CD103 populations to allow for antigen presentation. A 
recent study suggests that antigen transfer may occur between these populations via gap 
junctions 56. However, despite these recent findings, it remains unclear whether distinct 
subsets within the CX3CR1+ population are responsible for antigen uptake or whether 
antigen uptake is a function of all CX3CR1+ cells. Therefore, I wanted to assess antigen 
uptake among intestinal APC subsets as defined using the method described in this Chapter. 
 
Intestinal DC drain to the MLN where they can interact with T cells and influence immune 
responses. Therefore, the MLN consists of migratory DC populations originating from the 
LP and lymph node resident DC. Under homeostatic conditions, DC from the MLN can be 
categorised into four populations based on cell surface expression of CD103 and CD11b. Of 
these subsets, CD103+ CD11b+ cells are unique to the MLN and have a similar phenotype 
to DC reported in the LP. Therefore, it is likely these DC originated in the LP and migrated 
to the MLN 109. In addition, CD103+ CD11b- cells are thought to originate in the Peyer’s 
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patches, isolated lymphoid follicles and possibly the LP and are therefore likely to be 
contributing to the CD103+ CD11b- subset in the MLN 101. Both CD103+ CD11b+ and 
CD103+ CD11b- populations have the capacity to present orally delivered antigen 109 and 
are required to drive Treg development through production of chemical mediators such as 
retinoic acid (RA) and TGF-β 57, 58 . CD103+ DC populations are specifically equipped to 
express the enzyme retinal dehydrogenase (RALDH) which allows for the conversion of 
dietary vitamin A derivatives to RA. In this context, RA is not only important for driving the 
development of Tregs in the MLN but also for the upregulation of gut homing receptors 
such as CCR9 and 47 that facilitate the entry of T cells into the LP 57, 167, 168. In contrast, 
CD103- CD11b+ and CD103- CD11b- lymph node resident populations lack the ability to 
present oral antigen and promote upregulation of CCR9 109. These observations would 
suggest that only DC populations that have originated in the LP have the capacity to regulate 
intestinal homeostasis. However, it is unclear whether distinct subsets within the CD103+ 
population migrate at steady-state and are responsible for Treg induction or whether this is a 
characteristic of all CD103+ DC. Furthermore, it is not clear whether other LP resident DC 
have the capacity to migrate to the MLN. Therefore, I sought to assess the composition of 
DC subsets present in the MLN at steady-state using the same strategy used to assess LP 
APC. 
 
In order to gain a better understanding of the phenotype and function of intestinal APC I 
analysed APC from the LP and MLN of naïve mice for expression of a range of DC and Mφ 
markers. In addition to the classical markers for identifying DC, I chose to assess markers 
associated with Mφ such as F4/80 and TIM-4 and other non-conventional DC populations 
such as CD64. My results showed that LP CD11b+ APC could be divided into three distinct 
subsets, including CD103+ TIM-4- DC, CD103- TIM-4+ Mφ and a heterogeneous 
population of CD103- TIM-4- cells. In addition, I found LP Mφ to express CX3CR1, F4/80 
and CD64 and are highly efficient at antigen uptake in vivo whereas LP DC showed high 
activity of RALDH and appear to constitute a migratory MHCIIhi DC population in the 
MLN. Therefore, assessing intestinal APC for expression of CD103 and TIM-4 may be a 
useful method to assist in the identification of distinct APC populations in the intestine.  
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3.2. Aims 
 
Since the establishment of two broad CD11c+ MHCII+ subsets in the intestinal LP, further 
study of these subsets has been limited. Study of splenic, skin and lung resident DC has 
shown that there are many subsets of DC, each with distinct functions 169, 170, 171, 172. This 
chapter summarises my characterisation of intestinal DC and Mφ at steady-state.  
 
My specific aims were: 
 
1. To assess LP and MLN APC for expression of a range of cell surface molecules to 
determine if established populations could be further divided into distinct subsets.  
 
2. To investigate functional characteristics of APC subsets in terms of capacity to 
metabolise retinoic acid as determined by activity of RALDH and capacity for 
antigen uptake in vivo. 
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3.3. Results 
 
3.3.1. LP APC phenotype and subset compositions at steady-state 
 
Previous studies have found the composition of LP APC subsets to differ significantly from 
other tissues. Therefore, I was interested to determine the phenotype of small intestinal LP 
resident APC subsets at steady-state. The small intestine is divided into three histologically 
distinct sections; the duodenum, the jejunum and the ileum that can vary in length between 
mice 173. The jejunum and proximal ileum are the most commonly studied sections from the 
small intestine in mice 42, 101, 102 and share similar APC compositions 102. For consistency I 
focused solely on APC isolated from a section of the jejunal LP in this study. Since I was 
unable to analyse histological sections for each specimen studied, our lab adopted a strategy 
that defines small intestinal sections by measurement. The duodenum is defined as the first 
1.5cm of intestine beginning at the base of the stomach. The jejunum begins at the end of 
the duodenum and included the next 8cm of intestine. Lastly, the ileum is taken proximal to 
the cecum and includes the next 8cm of intestine above. To prevent lymphoid cell 
contamination, Peyer’s patches were excised from each section prior to analysis.  
 
APC isolated from the jejunal sections of naïve mice were identified by co-expression of 
CD11c and MHCII and found to account for approximately 20% of the total cellularity in 
the LP (Fig. 3.1, A). I found CD11c+ MHCII+ cells could be divided into four subsets 
based on cell surface expression of CD103 and CD11b. Approximately 90% of CD11c+ 
MHCII+ cells were CD11b+ among which 25% were CD103+. The full gating strategy I 
used to identify intestinal APC can been found in Appendix I. Interestingly, I found 
expression of the activation markers MHCII and CD86 to be significantly higher on CD103- 
CD11b+ APC compared to other APC subsets at steady-state (Fig. 3.2). This data shows LP 
resident APC are predominantly made up of CD11b+ cells at steady-state which can be 
further divided into CD103+ and CD103- subsets.  
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Figure 3.1: APC subsets from the jejunal LP 
Cells isolated from the jejunal LP of naïve mice were stained and analysed by flow cytometry. DC 
were identified by CD11c and MHCII staining. DC were divided into subsets based on cell surface 
expression of CD103 and CD11b.  Frequency of DC subsets are shown on FACS dot plots (A) and 
bar graph (B). Graph shows mean ± SEM of four independent experiments each including 3 mice 
per group. 
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Figure 3.2: Activation status of LP APC subsets 
APC isolated from the jejunal LP of naïve mice were examined for activation marker expression by 
flow cytometry. MHCII (A) and CD86 (B) staining is shown on histograms for individual DC 
subsets (coloured line) as compared to FMO controls (shaded). Quantification was determined by 
MFI as shown on bar graphs.  Bar graphs show combined mean ± SEM of four independent 
experiments each with 3 mice per experimental group. Statistical significance was determined by 
One-Way ANOVA with Bonferroni post-test. * p<0.05, **** p<0.0001. 
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3.3.2. CD103 and TIM-4 expression clearly defines three populations of CD11b+ 
APC in the LP at steady-state 
 
Next I was interested to further characterise CD11b+ CD103+/- populations from the LP. 
To do this, I isolated APC from the jejunal LP of naïve mice and analysed them for the 
expression of a range of cell surface markers including CD11c, CX3CR1, F4/80, CD64 and 
TIM-4. From these studies, I found CD103- APC populations to have lower expression of 
DC marker CD11c compared to CD103+ APC populations (Fig. 3.3, A). Furthermore, 
CD103- CD11b+ cells, but not CD103+ cells expressed the Mφ markers CX3CR1, F4/80 
and CD64 (Fig. 3.3., B-D). The CD103- CD11b- population showed intermediate expression 
of F4/80 and had bimodal expression of CD64. Interesting, I also found that CD103- 
CD11b- cells had bimodal expression of TIM-4. Therefore, I analysed CD103- CD11b- 
CD64+ and CD103- CD11b- CD64- populations separately for expression of TIM-4. I 
found approximately 75% of CD103- CD11b- CD64+ cells expressed TIM-4 compared to 
35% of CD103- CD11b- CD64- cells. Furthermore, I found the CD103- CD11b+ APC 
population contained TIM-4+ and TIM-4- cells whereas CD103+ APC showed little to no 
expression of TIM-4 (Fig. 3.3, E). 
 
Expression of TIM-4 appeared to highlight two distinct populations within the CD103- 
populations. As CD103- CD11b+ cells constituted a significant population of LP resident 
APC at steady-state, I was interested to further characterise TIM-4+ and TIM-4- cells within 
this population to determine if there were additional phenotypic differences. TIM-4 was not 
found to be expressed on CD103+ populations at steady-state (Fig. 3.4, A-B), therefore, I 
hypothesised that TIM-4 expression may be associated with intestinal Mφ. Analysis by flow 
cytometry revealed CD103- CD11b+ TIM-4+ (CD103- TIM-4+) cells to have significantly 
higher expression of Mφ marker CX3CR1 compared to CD103- CD11b+ TIM-4- (CD103- 
TIM-4-) cells (Fig. 3.4, C). Furthermore, approximately 80% and 100% of CD103- TIM-4+ 
cells express F4/80 and CD64 respectively. In comparison only 45% F4/80+ and 60% 
CD64+ cells were detected among CD103- TIM-4- cells (Fig. 3.4, D-E). In summary, this 
data shows cell surface expression of CD103 and TIM-4 can be used to clearly identify three 
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phenotypically distinct populations among CD11b+ LP resident APC (CD103+ TIM-4-, 
CD103- TIM-4+ and CD103- TIM-4-). 
Chapter 3: Phenotypic characterisation of intestinal APC subsets at steady-state 
 
52 
 
Figure 3.3: Cell surface marker expression on LP APC 
DC isolated from the jejunal LP of naïve mice were assessed for cell surface marker expression by 
flow cytometry. CD11c (A), CX3CR1 (B), F4/80 (C), CD64 (D) and TIM-4 (E) staining is shown on 
histograms for individual DC subsets (coloured line) compared to FMO or isotype controls (shaded). 
Bar graphs show MFI or the frequency of positive cells within each DC subset. Graphs show mean 
± SEM of two to four independent experiments, each with 3 mice per experimental group. 
Chapter 3: Phenotypic characterisation of intestinal APC subsets at steady-state 
 
53 
 
Chapter 3: Phenotypic characterisation of intestinal APC subsets at steady-state 
 
54 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: CD103- CD11b+ APC can be divided into two distinct populations 
DC were isolated from the jejunal LP of naïve mice and CD11b+ DC were assessed for cell surface 
expression of CD103 and TIM-4. Frequency of DC subsets among total CD11b+ CD11c+ MHCII+ 
cells are shown on pseudo colour plots (A) and stacked bar graph (B). Histograms are gated on 
CD11b+ CD103- TIM-4- (green line, left column) and CD11b+ CD103- TIM-4+ (green dashed 
line, right column) and show expression of CXCR1 (C), F4/80 (D) and CD64 (E) . All surface 
marker expression is compared to FMO or isotype controls (shaded areas). Bar graphs display MFI 
or frequency of positive cells within each subset. Graphs show mean ± SEM of two to four 
independent experiments, each with 3 mice per experimental group Statistical significance was 
determined by a Student’s unpaired t-test. *** 0.0001<p<0.001, **** p<0.0001 
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3.3.3. CD103- TIM-4+ APC take up antigen at steady-state 
 
CX3CR1+ Mφ have been shown to sample antigen directly from the intestinal lumen 
75. I 
found CD103- TIM-4+ cells to be phenotypically similar to reported CX3CR1+ Mφ. 
Therefore, I was interested to determine whether CD103- TIM-4+ cells shared functional 
characteristics of CX3CR1+ Mφ. To address this, mice were gavage fed OVA labelled with 
AF647 in combination with cholera toxin (CT). APC were isolated from the LP one hour 
later and assessed for AF647 fluorescence. I found that antigen was predominantly taken up 
by CD103- APC (Fig. 3.5, A). Closer examination revealed approximately 8% of CD103- 
TIM-4+ cells were positive for OVA-AF647 antigen compared to 1.5% of CD103- TIM-4- 
cells. Furthermore, minimal AF647+ cells were found among other LP resident APC subsets 
(Fig 3.5, B-C).  This data suggests the CD103- TIM-4+ subset is the most efficient of the LP 
resident APC subsets in taking up luminal antigen at steady-state. 
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Figure 3.5: CD11b+ TIM-4+ APC take up antigen at steady-state 
Cells were isolated from the jejunal LP one hour after mice were administered 250µg OVA-AF647 
with 10µg cholera toxin (CT) by oral gavage. Uptake of OVA-AF647 by LPDC populations was 
analysed by flow cytometry.  A) Contour flow plots show OVA-AF647 staining among CD11b+ 
CD11c+ MHCII+ cells.  B) Histograms show expression of OVA -AF647 by DC subsets. (C) Bar 
graphs show frequency of AF647+ among individual DC subsets. Graph shows mean ± SEM. n=3. 
Statistical significance was determined by One-Way ANOVA with Bonferroni post-test. *** 
0.0001<p<0.001, **** p<0.0001. Data is representative of three independent experiments. 
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3.3.4. CD103+ CD11b+ LP APC have high activity of RALDH at steady-state 
 
RALDH dependent RA metabolism by CD103+ DC has been reported to be important for 
driving differentiation of Tregs at steady-state 57, 58. I used an ALDEFLUOR™ assay kit to 
assess the activity of RALDH among LP resident APC subsets. The ALDEFLUOR™ 
substrate fluoresces upon interaction with the active RALDH enzyme, allowing for 
quantitative analysis of enzyme activity by flow cytometry. The RALDH inhibitor DEAB is 
added to control samples to determine background fluorescence. I found that CD103+ cells 
show the highest RALDH activity (Fig. 3.6, A). Among the CD103+ compartment, 
CD103+ CD11b+ DC had significantly higher frequency of cells expressing active RALDH 
compared to CD103+ CD11b- DC (Fig. 3.6, B-C). Interestingly, among CD103- CD11b+ 
cells I found TIM-4+ cells to show no RALDH activity whereas the TIM-4- cells showed 
modest RALDH activity, with up to 30% of cells expressing active RALDH. These results 
show that CD103+ CD11b+ DC have significantly higher frequencies of cells expressing 
RALDH, however, other LP resident APC populations also have some RALDH activity at 
steady-state. 
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Figure 3.6: CD103+ LPDC have active RALDH at steady-state 
Cells isolated from the jejunal LP of naïve mice were assessed for RALDH expression using an 
ALDEFLUOR staining kit. (A) Contour flow plots show ALDEFLUOR staining among CD11b+ 
CD11c+ MHCII+ cells compared to cells treated with RALDH inhibitor diethylaminobenzaldehyde 
(DEAB). B) Histograms show ALDEFLUOR staining for individual DC subsets compared to 
DEAB treated control cells. C) Bar graph shows frequency of ALDEFLUOR+ cells within each DC 
subset. Graph shows mean ± SEM. n=3. Statistical significance was determined by One-Way 
ANOVA with Bonferroni post-test. **  0.001<p<0.05, *** 0.0001<p<0.001, **** p<0.0001. Data is 
representative of four independent experiments. 
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3.3.5. MLN DC phenotype and subset compositions at steady-state 
 
LP APC acquire antigen and migrate to the MLN where they present antigen to T cells and 
initiate appropriate immune responses 55, 111. Therefore, I was interested to gain an 
understanding of the composition of MLN DC populations at steady-state. To do this, APC 
were isolated from the MLN of naïve mice and analysed for expression of cell surface 
markers by flow cytometry. On average, DC made up 1.5% of lymph node resident cells 
with 0.5% of DC showing a CD11c+ MHCIIhi phenotype and 1% a CD11c+ MHCIIint 
phenotype. Each of these major DC populations could be could be further divided into four 
subsets based on cell surface expression of CD103 and CD11b. I found CD103+ CD11b+ 
and CD103+ CD11b- DC to be enriched in the CD11c+ MHCIIhi fraction and CD103- 
CD11b+ and CD103- CD11b- DC to be enriched in the CD11c+ MHCIIint fraction (Fig. 
3.7). The full gating strategy can be found in Appendix II. Furthermore, I found CD11c+ 
MHCIIhi DC to show elevated expression of the co-stimulatory molecule CD86 compared 
their CD11c+ MHCIIint counterparts (Fig. 3.8, A). In addition, there was modest expression 
of TIM-4 (Fig. 3.8, B) and little to no expression of the Mφ markers F4/80, CX3CR1 and 
CD64 on any of these DC subsets in the MLN (Fig. 3.8, C-E). In summary, I found two 
distinct populations of DC in the MLN at steady-state which can be identified by their 
differential expression of CD103, MHCII and CD86. 
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Figure 3.7: DC subsets in the MLN 
Cells isolated from the MLN of naïve mice were stained and analysed by flow cytometry. DC were 
identified by CD11c and MHCII staining. MHCIIhi and MHCIIint DC were divided into subsets 
based on cell surface expression of CD103 and CD11b.  Frequencies of DC subsets are shown on 
FACS dot plot (A) and bar graph (B). Graph shows mean±SEM of four independent experiments, 
each with 3 mice per experimental group. 
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Figure 3.8: Cell surface markers on DC in the MLN 
DC isolated from the MLN of naïve mice were assessed for cell surface markers by flow cytometry. 
CD86 (A), TIM-4 (B), CX3CR1 (C), F4/80 (D) and CD64 (E) staining is shown on histograms for 
MHCIIhi (solid line) and MHCIIint (dashed line) DC subsets compared to FMO or isotype controls 
(shaded). Bar graphs show MFI or the frequency of positive cells within each DC subset. Graphs 
show mean ± SEM of two to four independent experiments.  
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3.3.6. MHCIIhi DC from the MLN have a high frequency of cells expressing active 
RALDH 
 
At steady-state, naïve T cells in the MLN are directed toward Treg differentiation, in part, 
through DC production of TGFβ and RA 57, 58. Examination of RALDH activity in each DC 
subset from the MLN using the flow cytometry ALDEFLUOR™ assay showed the 
CD11c+ MHCIIhi DC to have a higher frequency of RALDH+ cells compared to CD11c+ 
MHCIIint DC (Fig. 3.9, A).  Among the MHCIIhi population, CD103+ CD11b+ and 
CD103+ CD11b- DC had a significantly higher frequency of cells with RALDH activity 
compared to CD103- DC subsets. Little to no RALDH activity was detected in MHCIIint 
populations, apart from a small population of MHCIIint CD103+ CD11b- DC, which 
appeared to have high RALDH activity (Fig. 3.9, B-C). This data shows CD11c+ MHCIIhi 
CD103+ DC to be the predominant source of cells with RALDH activity at steady-state in 
the MLN. 
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Figure 3.9: CD103+ DC in the MLN have active RALDH at steady-state 
Cells isolated from the MLN of naïve mice were assessed for RALDH expression using an 
ALDEFLUOR staining kit. (A) Contour flow plots show ALDEFLUOR staining among CD11c+ 
MHCIIhi and CD11c+ MHCIIint cells compared to cells treated with RALDH inhibitor 
diethylaminobenzaldehyde (DEAB). B) Histograms show ALDEFLUOR staining for MHCIIhi (solid 
line) and MHCIIint (dashed line) DC subsets compared to DEAB treated control cells (shaded). C) 
Bar graph shows frequency of ALDEFLUOR+ cells within each DC subset. Graph shows mean ± 
SEM. n=3. Data is representative of four independent experiments.  
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3.4. Discussion 
 
Intestinal APC drive tolerogenic responses at steady-state in order to maintain homeostasis. 
However, the distinction between DC and Mφ populations and their functions under 
homeostatic conditions remains ambiguous. Experiments in this Chapter show a novel 
method of characterising CD11c+ MHCII+ cells from the LP and MLN at steady-state. I 
found cell surface expression of CD103 and TIM-4 could identify three distinct subsets of 
CD11b+ APC in the LP. TIM-4 expression by CD103- CD11b+ cells correlated with cells 
of a Mφ phenotype capable of antigen uptake in vivo whereas CD103+ CD11b+ and 
CD103+ CD11b- DC showed superior activity of the enzyme RALDH, required for Treg 
induction, in both the LP and MLN. Therefore, I propose this is a robust strategy for 
identifying subsets of intestinal APC at steady-state and may be useful for future study. 
 
3.4.1. LP CD11b+ APC subsets at steady-state 
 
At steady-state, I found I could classify CD11b+ APC from the jejunal LP into three distinct 
populations based on cell surface expression of CD103 and TIM-4. Specifically these 
populations were: CD103+ TIM-4-, CD103- TIM-4+ and CD103- TIM-4-. Intestinal 
CD11b+ APC have been divided into two distinct populations, namely, CD103+ DC and 
CX3CR1+ Mφ. Therefore, I hypothesised that CD103+ TIM-4- cells were phenotypically 
similar to migratory CD103+ DC that drive Treg differentiation at steady-state, whereas, 
CD103- TIM-4+ and CD103- TIM-4- were phenotypically similar to CX3CR1+ Mφ 
responsible for luminal antigen uptake. 
 
In support of this hypothesis I found CD103+ TIM-4- cells to express RALDH, an enzyme 
associated with CD103+ DC that promote Treg differentiation 57, 58. Furthermore, CD103+ 
TIM-4- cells that lacked expression of the Mφ markers CX3CR1, F4/80 and CD64, were 
unable to take up antigen in vivo and had high expression of the DC marker CD11c. Thus, 
this data suggests CD103+ TIM-4- cells have a phenotype consistent with that of intestinal 
DC. In contrast, I found CD103- TIM-4+ cells expressed CX3CR1, F4/80 and CD64. 
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CD103- TIM-4+ cells showed decreased CD11c expression compared to CD103+ TIM-4- 
DC and lacked activity of RALDH. CD103- CD11b+ cells, which include CD103- TIM-4+ 
cells, showed significantly higher expression of activation markers MHCII and CD86 
compared to other APC subsets. CX3CR1+ Mφ have previously been shown to localise to 
the epithelial barrier, allowing for increased exposure to microbial products 75, which may 
explain the increased basal expression of these activation markers. Furthermore, following 
administration of fluorescent OVA antigen, I found CD103- TIM-4+ cells to be highly 
efficient at antigen uptake. Therefore, this data indicates that CD103- TIM-4+ cells are 
phenotypically and functionally similar to intestinal resident Mφ. 
 
In contrast to my hypothesis, I found the CD103- TIM-4- subset to be a heterogeneous 
population that likely consists of a mixture of DC and Mφ. Phenotypic analysis of this 
population found expression of CX3CR1 and F4/80 was significantly lower than CD103- 
TIM-4+ Mφ. In addition, approximately 40% of CD103- TIM-4- cells were CD64- which 
suggests they are not of monocytic lineage. Interestingly, I found 30-35% CD103- TIM-4- 
cells to be RALDH+. Together these observations indicate that up to 40% of the CD103- 
TIM-4- population may have phenotypic features similar to that of intestinal DC. This 
interpretation is supported by recent studies which show that a proportion of CX3CR1+ 
cells express DC specific protein zBTB46 103. However, further investigation is required to 
confirm the lineage of the CD103- TIM-4- CD64- cells. Furthermore, a small population of 
CX3CR1
int cells have been reported in the LP at steady-state. These cells are thought to be 
more similar to DC than Mφ as they expand in response to Flt3L and are able to drive T cell 
proliferation 42. However, like Mφ, they originate from monocytic precursors and thus, these 
DC express CD64, a marker which has been previously used to identify intestinal Mφ 113.  
Due to the lower expression of CX3CR1 among CD103- TIM-4- cells, it is possible that a 
population of moDC also reside within this gate. Finally, I found a significantly lower 
frequency of CD103- TIM-4- cells took up antigen in vivo compared to CD103- TIM-4+ 
cells. This would suggest that the LP resident Mφ that lack expression of TIM-4 may be 
functionally distinct from CD103- TIM-4+ Mφ. 
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In summary, by using CD103 and TIM-4 expression to characterise intestinal CD11b+ APC 
subsets I highlighted the presence of three distinct populations of APC in the LP at steady-
state. CD103+ TIM-4- DC are phenotypically similar to the tolerogenic CD103+ DC 
reported in the literature. In addition, CD103- TIM-4+ Mφ share phenotypic and functional 
similarities to CX3CR1+ Mφ. However, the CD103- TIM-4- cells made up a heterogeneous 
population of DC and Mφ, which have previously not been characterised. These DC and Mφ 
may play different roles to earlier described DC and Mφ in maintaining tolerance at steady-
state and may provide an interesting avenue for further study.  
  
3.4.2. LP CD11b- APC subsets at steady-state 
 
In addition to CD11b+ APC, I found that the jejunal LP contains small numbers of 
CD103+ CD11b- and CD103- CD11b- cells, however, the frequency of these cells varied 
significantly between mice. CD103+ CD11b- cells lacked expression of the Mφ markers 
CX3CR1, CD64 and F4/80 but had some RALDH activity suggesting they are 
phenotypically similar to DC. CD103- CD11b- cells showed some expression of the Mφ 
markers F4/80, CD64 and TIM-4 but also showed some RALDH activity suggesting this 
population likely consisted of a mixture of DC and Mφ. 
 
It has been proposed that CD103+ CD11b- cells, which are found in high numbers in 
lymphoid organs 104, can be found in the LP preparations if Peyer’s patches are not 
completely removed from the jejunal tissue 101. Furthermore, the frequency of CD103+ 
CD11b- cells is thought to be dependent on the section of intestine, with higher frequencies 
found closer to the stomach 102. Therefore, as I could not accurately account for the origin of 
CD103+ CD11b- cells in my preparations, I excluded this population from further analysis. 
 
3.4.3. MLN DC subsets at steady-state 
 
Analysis of MLN DC showed two distinct populations based on the level of MHCII 
expression. These two populations could be further divided into four subsets based on 
expression of CD103 and CD11b. In other lymph nodes, high expression of MHCII has 
Chapter 3: Phenotypic characterisation of intestinal APC subsets at steady-state 
 
67 
been correlated to migratory DC populations and intermediate expression with lymph node 
resident populations 44. However, this strategy has not been commonly utilised in the MLN. 
Therefore, I hypothesised that CD11c+ MHCIIhi cells were migratory DC that had migrated 
to the MLN from the intestine, whereas, CD11c+ MHCIIint cells were lymph node resident 
DC. 
 
In support of this hypothesis, I found the CD11c+ MHCIIhi population to have upregulated 
activation marker CD86 compared to the CD11c+ MHCIIint population. In addition, the 
CD11c+ MHCIIhi population was enriched for CD103+ CD11b- and CD103+ CD11b+ 
DC and these populations were shown to have high RALDH activity. Previous reports have 
shown CD103+ DC migrate from the intestine to the MLN to drive Treg differentiation at 
steady-state 55, 111. In contrast, the CD11c+ MHCIIint population was enriched for CD103- 
CD11b+ and CD103- CD11b- cells that showed little to no RALDH activity. In the LP, a 
large proportion of CD103- CD11b+ cells express the Mφ markers CX3CR1, F4/80 and 
CD64. There was little to no expression of these markers on any DC populations in the 
MLN which suggests LP Mφ do not migrate to the MLN. However, I found variable 
expression of TIM-4 among all MLN DC subsets. While TIM-4 has been associated with 
Mφ, others have shown that DC can upregulate TIM-4 upon activation 148. In contrast, the 
CD11c+ MHCIIhi population in the MLN appears to be enriched for RALDH CD103+ DC 
which may have migrated from the LP. These results suggest that the CD11c+ MHCIIhi cells 
contain APC that closely resemble cells from the LP and thus are likely to consist of the 
migratory DC population. Therefore, for my future studies I focused on CD11c+ MHCIIhi 
cells. 
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3.5. Conclusions 
 
The population of intestinal APC is diverse, complex and unlike that of other tissues. 
Therefore, the understanding of the composition of steady-state APC subsets and their 
functions is incomplete. In this chapter, I show the characterisation of LP APC by assessing 
expression CD103 and TIM-4 and of MLN DC by assessing level of MHCII expression. 
CD103+ TIM-4- DC express high levels of RALDH and can be found in the LP and among 
CD11c+ MHCIIhi cells in the MLN. On the other hand, CD103- TIM-4+ cells are found in 
the LP and possess phenotypic and functional characteristics of Mφ. These include the 
expression of CX3CR1, CD64 and F4/80 and a high efficiency of antigen uptake in vivo. 
Finally, CD103- TIM-4- cells appear to comprise of a heterogeneous population that most 
likely consists of cells of the DC and Mφ lineage. From data presented in this chapter, I 
show that APC subsets in the intestine are highly heterogeneous at steady-state. I propose 
that CD103 and TIM-4 expression in the LP and MHCII expression in the MLN will be 
useful in future studies to help identify functionally distinct DC and Mφ populations in the 
intestine. This question will be examined later in this thesis (Chapter 5). 
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4.1. Introduction  
 
Intestinal APC are specialised to drive tolerogenic responses at steady-state while 
maintaining the capacity to recognise and initiate effector responses to pathogenic microbes 
and helminths 81. Although the mechanisms by which intestinal APC differentiate between 
innocuous and harmful antigens is currently unknown, mucosal adjuvants and inflammatory 
stimuli can alter intestinal APC phenotype and function. Changes in phenotype and subset 
composition may promote the initiation of immune responses in the intestine. Despite this, 
there is a lack of information on direct comparison between small intestinal APC 
populations at steady-state and following administration of a mucosal adjuvant. Study of 
APC following a mucosal adjuvant may provide insight into the processes that lead to the 
development of immunity in the intestine. 
 
At steady-state, CD103+ CD11b+ DC play a critical role in driving tolerance by promoting 
differentiation of Tregs in the LP and MLN 57, 58. However, CD103+ CD11b+ DC also play 
an important role in the direction of effector Th1/Th17 responses 81, 102 and IL-22/23 
responses to TLR5 ligands 174. Danger signals promote the accumulation of CD103+ 
CD11b+ DC in the LP and MLN 86, 175 and promote phenotypic and functional changes 
within this population. For example, Salmonella challenge has been shown to induce the 
mobilisation of CD103+ CD11b+ DC to the epithelial barrier to capture bacteria in a 
chemokine and TLR-dependent fashion 70, 72. In addition, CD103+ CD11b+ DC isolated 
from the MLN following the initiation of effector responses, have significantly lower 
expression of the genes associated with production of tolerogenic chemical mediators TGFβ 
and RA and increased expression of pro-inflammatory genes such as tbet and il-12p35 175. 
However, it has yet to be determined whether there are distinct subsets within the CD103+ 
CD11b+ population that preferentially promote different immune responses, or whether 
environmental cues act on the population as a whole to promote immunity.  
 
Under homeostatic conditions, monocytic precursors differentiate into tolerogenic, IL-10 
producing CX3CR1
hi Mφ and small numbers of CX3CR1
int DC 42, 134. During inflammation, 
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the composition of the monocyte-derived compartment changes and CX3CR1
int DC increase 
significantly in frequency in the LP. CX3CR1
int DC are thought to promote effector T cell 
responses in the intestine and have a pro-inflammatory genetic signature 99, 117, 134, 135 114. These 
DC, when isolated from inflamed colons, have been shown to drive CD4 T cell proliferation 
99 and IFNγ production 114 in vitro. Ablation of the CX3CR1
int population with an anti-CCR2 
antibody ameliorated DSS induced colitis, implicating these cells as the major drivers of 
colonic inflammation 99. However, the majority of study into intestinal moDC has been 
focused on the colon and it is not understood whether moDC play a role in driving 
immunity in the small intestine. 
 
While there is some understanding about the roles of APC subsets in the promotion of 
immunity in the colon, the roles of APC from the small intestine are less well defined. 
Cholera toxin (CT) is a potent mucosal adjuvant that drives immune responses to co-
delivered antigen in the small intestine 176. In addition, CT disrupts the epithelial barrier 
allowing for entry of commensal bacteria into the LP 177. Prolonged interaction between 
commensals and immune cells is known to cause chronic intestinal inflammation 178. I used 
oral administration of CT to study the effects of a mucosal adjuvant on the composition and 
phenotype of APC subsets from the small intestine in vivo. From these studies, I identified a 
novel phenotype of DC, characterised by co-expression of CD103 and TIM-4, which appear 
transiently in the LP and MLN following oral administration of CT. I propose that LP-
resident CD103+ DC upregulate TIM-4 upon exposure to CT and subsequently migrate to 
the lymph node. In the lymph node, CD103+ TIM-4+ DC may influence T cell responses 
and thus contribute to the initiation of immunity in the intestine.  
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4.2. Aims 
 
APC are important in regulating intestinal immune responses. Adjuvants and other 
stimulatory agents can alter the phenotype and function of APC and thus influence T cell 
responses. For these reasons, I was interested to assess the phenotype and subset 
composition of intestinal APC after oral administration of the mucosal adjuvant CT.  This 
chapter summarises my characterisation of intestinal APC subsets following oral 
administration of CT. 
  
Specifically my aims were: 
 
1. To determine whether APC subset compositions in the LP and MLN are altered 
following oral administration of CT. 
 
2. To assess the phenotype and origin of the populations that are altered following oral 
administration of CT. 
 
3. To assess the roles of commensal bacteria and TLR4 signalling in any observed 
changes to intestinal APC subsets following oral administration of CT. 
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4.3. Results 
 
4.3.1. Oral administration of cholera toxin changes the composition of APC subsets 
in the LP and MLN 
 
In Chapter 3, I showed that steady-state CD11b+ APC can be divided into three distinct 
populations based on expression of CD103 and TIM-4: CD103+ TIM-4- DC, CD103- TIM-
4+ Mφ and a heterogeneous population of CD103- TIM-4- cells. Using this method, I 
wished to compare the composition of APC subsets after CT treatment and in the steady-
state. To address this, mice were gavage fed the mucosal adjuvant CT with OVA antigen 
(OVA+CT). Cells were isolated from the LP and MLN 17 hours later and assessed for 
expression of cell surface markers.  
 
I found that CT treatment did not result in significant changes to the frequency of total 
number of CD11c+ MHCII+ APC in the LP. Furthermore, the frequency of APC subsets 
as determined by CD103 and CD11b staining (CD103+ CD11b-, CD103+ CD11b+, 
CD103- CD11b+ and CD103- CD11b-) did not change between steady-state and CT 
treatment (Fig. 4.1, A). I observed approximately 50% of CD103+ CD11b+ cells expressed 
the cell surface marker TIM-4. Therefore, CD11b+ APC from OVA+CT treated mice could 
be divided into four distinct populations due to the appearance of CD103+ TIM-4+ cells in 
the LP (Fig. 4.1, A-B). In addition to examining expression of CD11b, CD103 and TIM-4, I 
also assessed the expression of the activation marker CD86 on LP APC subsets. I found that 
OVA+CT treatment resulted in a significant upregulation of CD86 on CD103+ CD11b+ 
and CD103+ CD11b- LP APC (Fig. 4.1, C). 
 
Similar to the LP, the composition of MLN CD11c+ MHCIIhi DC subsets did not change 
between naïve and OVA+CT treated mice. However, the proportion of TIM-4+ cells 
among CD103+ CD11b+ DC increased on average from 20% to 50% following OVA+CT 
(Fig. 4.2, A-B). Although not significant in all experiments carried out, CD86 expression 
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tended to be higher on CD103+ DC after CT treatment compared to steady-state (Fig. 4.2, 
C). 
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Figure 4.1: CT induces the appearance of a novel phenotype of APC in the LP 
LP cells isolated from naïve or OVA+CT treated mice were stained and analysed by flow cytometry. APC 
were identified by CD11c and MHCII staining and then divided into subsets based on cell surface expression 
of CD103, TIM-4 and CD11b.  Gating strategy to classify APC subsets from the jejunal LP are shown on 
FACS dot plots (A). Bar graphs show frequency of each APC subset from the LP (B) and CD86 MFI on 
CD11b+ APC (C). Graph shows combined mean ± SEM of four independent experiments, each of which 
included 3 mice per experimental group.  Statistical significance was determined by Student’s unpaired t-test. 
* p<0.05, **  0.001<p<0.05 
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Figure 4.2: CT increases the frequency of CD103+ CD11b+ TIM-4+ APC in the 
MLN 
MLN cells isolated from naïve or OVA+CT treated mice were stained and analysed by flow 
cytometry. APC were identified by CD11c and MHCII staining and then divided into subsets based 
on cell surface expression of CD103, TIM-4 and CD11b.  Gating strategy to classify APC subsets 
from the MLN are shown on FACS dot plots (A). Bar graphs show frequency of each APC subset 
from the MLN (B) and CD86 MFI on each APC subset (C). Graph shows combined mean ± SEM 
of four independent experiments, each of which included 3 mice per experimental group. 
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4.3.2. CT is sufficient to induce the appearance of CD103+ TIM-4+ DC in the 
intestine 
 
Oral administration of CT in combination with OVA protein leads to an increase in the 
frequency of CD103+ TIM-4+ cells in the LP and MLN. Although not significant in all 
experiments, similar results can be observed in mice co-administered BSA protein and CT. 
However, I found administration of CT alone in PBS did not alter APC subset compositions 
from steady-state. Thus, I hypothesised the activity of CT was being compromised by the 
acidity of the stomach and co-administration with a large bolus of protein such as OVA or 
BSA was protecting CT from degradation. To test this hypothesis, CT was administered in 
bicarbonate buffer (pH 9.6) to increase the pH of the stomach. This experiment showed CT 
induced a similar increase in the frequency of CD103+ TIM-4+ cells compared to CT 
combined with OVA or BSA (Fig. 4.3). This data demonstrates that CT is responsible for 
the change in APC subset composition I observe following oral administration of 
OVA+CT.  
 
4.3.3. CD103+ TIM-4+ cells appear transiently in the intestine following OVA+CT 
treatment 
 
As I could detect CD103+ TIM-4+ DC at increased frequencies in both the LP and MLN, I 
was interested to determine the kinetics of CD103+ TIM-4+ cells in order to gain a better 
understanding of their origin and migratory capacity. To do this, cells were isolated from the 
LP and MLN at different time points following oral administration of OVA+CT. I found 
that CD103+ TIM-4+ cells begun to appear in the LP from 8 hours post treatment, peaked 
in frequency at 17 hours and decreased in frequency from 24 hours (Fig. 4.4, A). In the 
MLN, CD103+ TIM-4+ cells could be detected from 12 hours post treatment and returned 
to baseline by 48 hours (Fig. 4.4, B). This data shows CD103+ TIM-4+ cells initially increase 
in frequency in the LP after CT treatment and can be detected in the MLN 4 hours later. 
The appearance of CD103+ TIM-4+ cells appears to be transient with the frequency of 
APC subsets from CT treated mice returning to steady-state by 48 hours in the MLN. 
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Figure 4.3: CT induces the appearance of CD103+ TIM-4+ APC in the LP and MLN 
Cells were isolated from mice treated with CT, OVA (O), OVA+CT or BSA (B)+CT in PBS (P) or 
bicarbonate buffer (HCO3) by oral gavage. Frequency of CD103+ TIM-4+ among CD11b+ APC 
from the LP (A) and TIM-4+ among CD103+ CD11b+ APC from the MLN (B) is shown on bar 
graphs. Graphs shown mean ± SEM. Graphs were prepared by combining data from three 
independent experiments. Statistical significance was determined by One-Way ANOVA with 
Bonferroni post-test. * p<0.05, *** 0.0001<p<0.001, **** p<0.0001 
 
 
 
 
Figure 4.4: CD103+ TIM-4+ APC appear transiently in the LP and MLN following 
CT administration 
Cells were isolated from mice 1-48 hours following intragastric OVA+CT administration. Frequency 
of CD103+ TIM-4+ APC among total CD11b+ APC from the LP (A) and TIM-4+ among 
CD103+ CD11b+ APC from the MLN (B) was determined by flow cytometry for each time point. 
Graphs shown mean ± SEM. Graphs were prepared by combining data from three independent 
experiments. Statistical significance was determined by One-Way ANOVA with Bonferroni post-test. 
* p<0.05, **  0.001<p<0.05, *** 0.0001<p<0.001, **** p<0.0001 
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4.3.4. CT reduces expression of CX3CR1 but not F4/80 or CD64 on CD103- APC 
 
As I could detect TIM-4 expression on CD103+ DC following CT treatment, I was 
interested to determine whether CT altered the expression of other cell surface markers on 
other APC subsets. Therefore, I compared cell surface expression of the lineage markers 
CX3CR1, F4/80 and CD64 among LP APC subsets from naïve and OVA+CT treated mice. 
Interestingly, I found that the expression of CX3CR1 decreased following CT treatment on 
both CD103- TIM-4+ Mφ and CD103- TIM-4- cells (Fig. 4.5, A). However, there was no 
difference in the expression of F4/80 or CD64 between steady-state and CT treatment in 
any of the LP APC populations (Fig. 4.5, B-C). 
 
4.3.5. CD103+ TIM-4+ cells are phenotypically similar to CD103+ TIM-4- DC 
 
The increase in frequency of CD103+ TIM-4+ cells was the most significant difference I 
observed between steady-state and CT treatment. Therefore, I was interested to further 
characterise CD103+ TIM-4+ cells. To do this, I examined the expression of lineage 
markers on CD103+ TIM-4+ cells. From these studies, I found CD103+ TIM-4- DC and 
CD103+ TIM-4+ cells lacked expression of Mφ markers CX3CR1 and F4/80, whereas these 
markers could be detected on the CD103- TIM-4+ Mφ population (Fig. 4.5, A-B).  CD64 is 
a monocyte lineage marker that is found on both Mφ and inflammatory DC populations 50, 
113. CD103+ TIM-4- DC and CD103+ TIM-4+ cells were found to express little to no 
CD64, whereas approximately 60% of CD103- TIM-4- cells and 95% of CD103- TIM-4+ 
Mφ express CD64 (Fig. 4.5, C).  
 
In addition to assessing cell surface lineage markers, I compared the cellular morphology of 
CD103+ TIM-4+ cells to previously characterised intestinal CD103+ TIM-4- DC and 
CD103- TIM-4+ Mφ populations. I used flow cytometry to sort individual LP CD11c+ 
MHCII+ populations from OVA+CT treated mice, and stained cells using DiffQuick to 
observe under the microscope. I found CD103+ TIM-4- cells to have the typical 
morphology of classical DC, with dendrite protrusions and an amorphous cytoplasm. 
Conversely, the CD103- TIM-4+ population had the typical morphology of Mφ, with many 
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phagocytic vacuoles in the cytoplasm. CD103- TIM-4- cells tended to be a heterogeneous 
population, with a morphology not typical of DC or Mφ. CD103+ TIM-4+ cells appeared 
round and had very few dendritic protrusions or cytoplasmic vacuoles (Fig. 4.6, A). Thus, 
the morphology of CD103+ TIM-4+ cells was observed to have features of both DC and 
Mφ. Importantly, flow cytometric analysis revealed CD103+ TIM-4+ cells to have forward 
and side scatter properties similar to those of CD103+ TIM-4- DC and not CD103- TIM-
4+ Mφ (Fig. 4.6, B). In summary, data from phenotypic, morphological and flow cytometry 
studies suggest that CD103+ TIM-4+ cells that appear following CT treatment are more 
similar to CD103+ TIM-4- DC than CD103- TIM-4+ Mφ. 
 
4.3.6. CT induces maturation of CD103+ TIM-4+ cells in the LP 
 
I showed that CT treatment induced the upregulation of the activation marker CD86 on 
CD11b+ APC from the LP (Fig. 4.1, C). Therefore, I was interested to assess whether CT 
preferentially induces maturation of specific subsets of APC in the intestine. I found the 
population of CD103+ TIM-4+ cells to have significantly elevated expression of CD86 
compared to CD103+ TIM-4- DC and CD103- TIM-4+ Mφ populations (Fig. 4.5, D). 
Interestingly, CD103+ TIM-4- DC showed similar CD86 expression between steady-state 
and inflammatory conditions. Therefore, this data suggests CD103+ TIM-4+ cells are 
accounting for the increase in CD86 expression observed among CD103+ CD11b+ cells 
(Fig. 4.1., C). 
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Figure 4.5: CD103+ TIM-4+ APC show increased activation and lack markers of Mφ 
lineage. 
LP APC were isolated from naïve mice or 17 hours following intragastric OVA+CT. Cell surface 
expression of CX3CR1 (A), F4/80 (B), CD64 (C) and CD86 (D) is shown on histograms for each 
subset (bold coloured line) compared to naïve mice (coloured line) and FMO or isotype controls 
(shaded). MFI or percent positive among APC subset are shown on corresponding bar graphs. 
Graphs show combined mean ± SEM of two to four independent experiments. Statistical 
significance was determined by One-Way ANOVA with Bonferroni post-test (A) or Student’s 
unpaired t-test (D). *** 0.0001<p<0.001, **** p<0.0001 
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Figure 4.6: CD103+ TIM-4+ APC share morphological characteristics of CD103+ 
TIM-4- DC and CD103+ TIM-4+ Mφ 
LP APC were isolated 17 hours following intragastric OVA+CT. CD103+ TIM-4-, CD103+ TIM-
4+, CD103- TIM-4- and CD103- TIM-4+ cells were flow sorted and stained with DiffQuick (A).Dot 
plots show FSC and SSC characteristics for each APC population following oral OVA+CT (B). 
 
 
4.3.7. CD103+ TIM-4- and CD103+ TIM-4+ cells express active RALDH 
 
I was interested to determine expression of the enzyme RALDH among APC subsets from 
the LP. RALDH has been shown to be highly active among CD103+ DC from the intestine. 
I measured RALDH activity by flow cytometry using the ALDEFLUOR assay and found 
that among CD103+ TIM-4- and CD103+ TIM-4+ populations, a similar proportion (70-
90%) of cells had detectable RALDH activity. In comparison, only 1-2% of CD103- TIM-
4+ Mφ and 20-25% of CD103- TIM-4- cells showed RALDH activity (Fig. 4.7, A-B). This 
data shows that CD103+ TIM-4+ cells have similar RALDH activity to intestinal CD103+ 
TIM-4- DC from CT treated mice. 
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Figure 4.7: CD103+ TIM-4- and CD103+ TIM-4+ APC show high RALDH activity 
LP APC were isolated 17 hours following intragastric OVA+CT. RALDH activity was determined 
using the ALDEFLUOR staining kit (A) and is shown for each subset (coloured line) compared to 
cells treated with RALDH inhibitor diethylaminobenzlaldehyde (DEAB) (shaded). (B) Frequency of 
RALDH positive cells within each APC subset. Bar graph shows combined mean ± SEM from three 
independent experiments. 
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4.3.8. TLR4 signalling is not required for the increased frequency of CD103+ TIM-
4+ cells in the LP and MLN following oral administration of CT 
 
Following CT treatment, I found CD103+ TIM-4+ DC to increase in frequency and 
intestinal APC elevate expression of CD86 compared to steady-state. I was interested to 
investigate possible mechanisms by which this occurs. TLR signalling is important for DC 
sensing of commensal and pathogenic bacteria. TLR4 binds LPS, a component of bacterial 
cell walls and has also been suggested to be involved in DC activation in response to CT 144. 
Furthermore, CT is known to cause epithelial barrier dysfunction, allowing for commensal 
bacteria to enter the LP and interact with DC. Therefore, I wanted to determine whether 
TLR4 was involved in the CT induced appearance of CD103+ TIM-4+ cells. To address 
this, OVA+CT was gavage fed to TLR4 deficient mice and CD103+ DC were analysed for 
TIM-4+ expression. I found the frequency of CD103+ TIM-4+ cells in the LP (Fig. 4.8, A-
B) and the MLN (Fig. 4.9, A-B) to be similar between TLR4-deficient and C57 mice 
following CT treatment suggesting that TLR4 signalling is not required for CT to induce the 
appearance of CD103+ TIM-4+ cells in the LP or MLN. Furthermore, expression of CD86 
on APC subsets in the LP (Fig. 4.8, C-D) and MLN (Fig. 4.9, C-D) was not significantly 
different between TLR4 deficient and C57 mice treated with CT. Therefore, APC activation 
in response to CT was independent of TLR4 signalling. 
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Figure 4.8: TLR4 is not required for the appearance of CD103+ TIM-4+ APC in the 
LP 
LP cells were isolated 17 hours following intragastric OVA+CT from TLR4-/- mice. Frequency of 
APC subsets is shown on dot plots (A) and quantified on stacked bar graphs (B) compared to APC 
subsets from  naïve TLR4-/- and OVA+CT treated C57 mice. To assess activation, CD86 expression 
is shown for each APC subset (coloured line) compared to FMO controls (shaded) on histograms (C) 
and quantified by CD86 MFI (D). Graphs show mean±SEM. 
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Figure 4.9: TLR4 is not required for the appearance of CD103+ TIM-4+ APC in the 
MLN 
 
MLN cells were isolated 17 hours following intragastric OVA+CT from TLR4-/- mice. Frequency of 
APC subsets is shown on dot plots (A) and quantified on stacked bar graphs (B) compared to APC 
subsets from  naïve TLR4-/- and OVA+CT treated C57 mice. To assess activation, CD86 expression 
is shown for each APC subset (coloured line) compared to FMO controls (shaded) on histograms (C) 
and quantified by CD86 MFI (D). Graphs show mean±SEM. 
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4.3.9. The increase in frequency of CD103+ TIM-4+ cells following oral CT is 
independent of intestinal commensal microbes 
 
Commensal bacteria in the intestine can influence DC phenotype and function via signalling 
through PRRs. Epithelial barrier dysfunction is associated with IBD, allowing for 
commensals to populate the LP. Therefore, movement of bacteria from the lumen to the LP 
due to CT induced barrier dysfunction may affect APC subset composition and activation. 
To determine whether commensal bacteria were involved in promoting the increase in 
frequency of CD103+ TIM-4+ cells, I supplemented drinking water with 5% DSS for 3-5 
days. In this model, by day 3, epithelial barrier integrity is compromised and commensals 
begin to populate the LP and by day 5 mice start to show symptoms of intestinal 
inflammation including the presence of fecal blood 179. However, when I analysed small 
intestine LP APC subset compositions at 3 or 5 days following DSS treatment I did not 
detect any significant changes compared to naïve controls. Furthermore, CD103+ TIM-4+ 
cells could not be detected in the LP at the time points analysed (Fig. 4.10, A-B) and the 
expression of CD86 on APC subsets following DSS treatment was similar to the expression 
on APC subsets from control mice (Fig. 4.10, C-D). These results suggest that commensals 
alone are unable to promote the expression of TIM-4 and CD86 on CD103+ APC after 
DSS treatment. 
 
To determine whether commensals play a role in altering DC subset composition when CT 
is administered, I treated mice with a pan antibiotic cocktail for 10 days, to significantly 
reduce microbes, prior to OVA+CT administration. Antibiotic treatment did not 
significantly alter steady-state APC composition or expression of CD86 (Fig. 4.11 and 4.12). 
Furthermore, there was no significant difference in the frequency of CD103+ TIM-4+ cells 
in the LP (Fig. 4.11, A-B) or MLN (Fig. 4.12, A-B) between mice treated with antibiotics and 
OVA+CT compared to control mice treated with OVA+CT. In addition, the expression of 
CD86 on intestinal APC from the LP (Fig. 4.11, C-D) and MLN (Fig. 4.12, C-D) did not 
differ significantly between OVA+CT treated mice with or without antibiotic treatment. 
These results suggest commensal bacteria are not playing a role in the appearance of 
CD103+ TIM-4+ cells or the activation of LP APC following CT treatment. 
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Figure 4.10: DSS induced colitis does not change small intestinal APC subset 
compositions significantly 
LP APC were isolated from the small intestine of mice treated with DSS in their drinking water for 3 
or 5 days. Frequencies of individual APC subsets are shown in dot plots (A) and quantified on a 
stacked bar graph (B). CD86 staining as shown for each APC subset (coloured line) compared to 
FMO controls (shaded) on histograms (C) was used to assess APC activation. Quantification was 
determined by CD86 MFI and shown on bar graphs. Graphs shown mean ± SEM. Data is 
representative of three independent experiments.  
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Figure 4.11: Commensal microbes are not required for the appearance of CD103+ 
TIM-4+ APC in the LP 
 
Mice were treated with an antibiotic cocktail (ampicillin, gentamicin, neomycin, metronidazole and 
vancomycin) for 10 days prior to intragastric challenge with OVA+CT. LP cells were isolated 17 
hours following intragastric OVA+CT. Frequency of APC subsets is shown on dot plots (A) and 
quantified on stacked bar graphs (B) compared to APC subsets from mice treated with or without 
antibiotics and OVA+CT. To assess activation, CD86 expression is shown for each APC subset 
(coloured line) compared to FMO controls (shaded) on histograms (C) and quantified by CD86 MFI 
(D). Graphs show mean±SEM. 
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Figure 4.12: Commensal microbes are not required for the appearance of CD103+ 
TIM-4+ APC in the MLN 
 
Mice were treated with an antibiotic cocktail (ampicillin, gentamicin, neomycin, metronidazole and 
vancomycin) for 10 days prior to intragastric challenge with OVA+CT. MLN cells were isolated 17 
hours following intragastric OVA+CT. Frequency of APC subsets is shown on dot plots (A) and 
quantified on stacked bar graphs (B) compared to APC subsets from mice treated with or without 
antibiotics and OVA+CT. To assess activation, CD86 expression is shown for each APC subset 
following OVA+CT administration (bold coloured line) with CD103+ TIM-4+ cells indicated by a 
dashed line compared to APC subsets from naïve mice (coloured line) and FMO controls (shaded) 
on histograms (C) and quantified by CD86 MFI (D). Graphs show mean±SEM. 
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4.4. Discussion 
 
Intestinal APC subsets drive tolerogenic responses to food antigens and commensal bacteria 
while maintaining the ability to mount immune responses to pathogens. It is currently not 
well understood which subsets are responsible for the recognition and induction of adaptive 
immune responses in the intestine. Therefore, I wanted to assess the phenotype of intestinal 
DC following administration of a mucosal adjuvant to determine if there was any significant 
change in the compositions of APC subsets compared to steady-state. Following oral 
administration of CT with OVA antigen, I identified a novel phenotype of CD103+ DC 
which express the cell surface molecule TIM-4 and increased levels of the co-stimulatory 
molecule CD86. The presence of CD103+ TIM-4+ DC appeared to depend on the activity 
of CT but did not require signalling from commensal bacteria or signalling through TLR4. 
CD103+ TIM-4+ DC could also be detected in the MLN, suggesting these DC migrate 
from the LP and may influence T cell phenotype and intestinal immunity. Therefore, I 
propose that CD103+ TIM-4+ DC may contribute to the development of immune 
responses following oral administration of CT. 
 
4.4.1. CD103+ DC upregulate TIM-4 in response to CT 
 
Oral administration of the mucosal adjuvant CT results in the appearance of a novel 
phenotype of CD11b+ APC in the LP and MLN characterised by co-expression of CD103 
and TIM-4. Currently, little is understood about the phenotype and function of intestinal 
APC subsets following administration of a mucosal adjuvant. At steady-state, there are three 
distinct populations of CD11b+ APC in the LP which I classified as CD103+ TIM-4- DC, 
CD103- TIM-4+ Mφ and a heterogeneous population of CD103- TIM-4- cells which likely 
include DC and Mφ. I hypothesised that CD103+ TIM-4+ cells detected after CT treatment 
were arising from one of these resident APC populations as opposed to being recruited to 
the LP from the blood.  
 
In support of my hypothesis I found that CD103+ TIM-4+ cells arise from resident 
CD103+ TIM-4- DC following oral administration of CT. Firstly, CT treatment did not alter 
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the frequency of total CD103+ CD11b+ cells in the LP (Fig. 4.1). The frequency of 
CD103+ TIM-4+ cells increased as the frequency of CD103+ TIM-4- DC decreased 
suggesting that CD103+ DC upregulate TIM-4 in response to CT. Secondly, CD103+ TIM-
4- and CD103+ TIM-4+ DC had high activity of the RA metabolising enzyme RALDH 
compared to CD103- populations. RALDH activity is strongly associated with intestinal DC 
and thus detection of RALDH activity within the CD103+ TIM-4+ population suggests 
these cells possess similar specialised function as the intestinal CD103+ DC population (Fig. 
4.6). Thirdly, CD103+ TIM-4+ cells do not express Mφ markers CX3CR1, F4/80 or CD64. 
Therefore, it is unlikely CD103+ TIM-4+ cells are derived from the CD103- TIM-4+ 
resident Mφ population or the CD103- TIM-4- population as they would have to lose 
expression of CX3CR1, F4/80 and CD64 as well as gain activity of RALDH and expression 
of CD103. Finally, as CD103+ TIM-4+ cells do not express CD64, it is unlikely they 
originate from monocytic precursors from the blood as inflammatory DC have been shown 
to express CD64 50. Together these data suggests CD103+ DC upregulate TIM-4 in 
response to oral CT.  
 
Expression of TIM-4 has been reported on Mφ populations in the lung145 and peritoneum146 
but has not been previously reported on DC populations in vivo. However, in vitro studies 
have shown CT and other DAMPs such as LPS can induce DC maturation and upregulation 
of TIM-4 147, 148. Thus, expression of TIM-4 may indicate DC maturation in vivo and may 
affect DC functions such as T cell priming capabilities. Further evidence to support this 
conclusion is the fact that CD103+ TIM-4+ cells express higher levels of the activation 
marker CD86 compared to other APC populations in the LP and total CD103+ populations 
from naïve mice. Although it is not clear from these studies, it would be of interest to 
determine whether a distinct subset of CD103+ DC upregulate TIM-4 in response to CT or 
whether CD103+ DC that have directly or indirectly interacted with CT upregulate TIM-4. 
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4.4.2. CT induced TIM-4 upregulation by CD103+ DC does not require signalling 
through TLR4 or from commensal bacteria 
 
Recognition of MAMPs and DAMPs via PRRs such as TLRs can influence APC phenotype 
and function 144, 148. In the intestine, signalling through PRRs as well as signals from 
commensal bacteria are important to maintain immune homeostasis at steady-state 64, 65, 66. 
Germ-free mice are deficient in these signals, and have high serum IgE titres and are prone 
to developing allergic diseases compared to littermate controls 94. In contrast, prolonged 
PRR signalling from commensals and direct interaction of commensals with APC has been 
implicated in the pathogenesis of IBD 178, 180. Thus, a unique paradigm exists in the intestine 
where PRR signals are required for the development of tolerance as well as inflammatory 
responses.  
 
In vitro studies have reported DC to mature and upregulate TIM-4 in response to DAMPs 
such as LPS. Others have suggested a key role for TLR4 signalling in CT induced TIM-4 
upregulation 144. In addition, CT is known to compromise epithelial barrier function allowing 
for movement of commensals into the LP and interact with APC 177. Therefore, I 
hypothesised that CD103+ DC may be upregulating TIM-4 expression in response to 
commensal microbial components through PRRs such as TLR4 following CT treatment. In 
contrast to my hypothesis, TIM-4 upregulation by CD103+ DC was independent of both 
TLR4 signalling and commensal bacteria as shown by experiments using TLR4 receptor 
deficient mice and antibiotic treatment. Although oral feeding of an antibiotic cocktail is not 
likely to deplete all bacteria from the intestine, treated mice had similar characteristics to 
germ-free mice including enlarged ceca, which would suggest the depletion was effective. 
Furthermore, introduction of commensals into the LP following DSS treatment failed to 
induce TIM-4 upregulation by DC. It is important to note the possibility that very few 
bacteria may translocate into the small intestinal LP. Although bacterial translocation was 
not measured in this study, reports have shown that the upper small intestine has a lower 
bacterial load compared to other regions of the intestine 181. Together, these experiments 
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would suggest that upregulation of TIM-4 on CD103+ DC depends on the activity of CT, 
rather than indirect action by microbiota. 
 
This is the first report of TIM-4 expression on a DC population in vivo. Therefore, it is 
possible that intestinal resident DC require different signals to upregulate TIM-4 in response 
to CT compared to in vitro generated BMDC that were studied in published reports 144. A 
recent study has shown that ganglioside signalling by epithelial cells and DC is the 
predominant mechanism by which intestinal DC mature in response to CT in vivo 160. Thus, 
ganglioside signalling may be involved in prompting TIM-4 upregulation by CD103+ DC in 
addition to maturation signals.  
 
4.4.3. CD103+ TIM-4+ DC are present in the lymph node 
 
CD103+ TIM-4+ DC were present in the lymph node from 12 hours post OVA+CT 
treatment. This suggests that CD103+ TIM-4+ DC will have the opportunity to interact 
with T cells and thus, may influence immune responses. CD103+ TIM-4- DC have been 
shown to have the capacity to migrate to the MLN 42 which is critical for the induction of 
immune responses to oral antigen 101. Furthermore, mice deficient in the lymph node 
homing receptor CCR7 have been shown to have a decreased frequency of CD103+ 
CD11b+ cells in the MLN 111 and fail to mount immune responses following oral 
immunisation 168. 
 
The data presented in this Chapter suggests that CD103+ TIM-4+ DC are derived from the 
migratory CD103+ TIM-4- population. If this is the case, CD103+ TIM-4- and CD103+ 
TIM-4+ DC may share similar migratory capabilities. Time course experiments revealed that 
CD103+ TIM-4+ DC appear in the LP and MLN from eight and twelve hours post 
OVA+CT respectively. This data suggests that following OVA+CT treatment the LP-
resident CD103+ upregulate TIM-4 and subsequently migrate to the MLN where they can 
be detected 4 hours later. Thus, CD103+ TIM-4+ DC may play a role in the driving effector 
immune responses to oral antigen in the presence of CT.  
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4.5. Conclusions 
 
The composition of intestinal APC following administration of a mucosal adjuvant and the 
role of individual APC subsets in driving effector T cell responses are not well understood. 
In this chapter, I demonstrate a proportion of CD103+ DC alter their phenotype and 
morphology in response to CT induced inflammation. This population can be characterised 
by co-expression of CD103 and TIM-4 and elevated expression of the activation marker 
CD86. These changes in phenotype appear to be independent of TLR4 signalling and DC 
interaction with commensal bacteria, but require CT. In addition, CD103+ TIM-4+ DC 
appear to have the capacity to migrate to the MLN and thus may influence T cell responses. 
I propose CD103+ TIM-4+ DC may be playing a role in influencing intestinal immune 
responses. Further study of this subset may provide insight into processes contributing to 
intestinal pathologies such as food allergy and IBD. 
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5.1. Introduction 
 
CT can promote the induction of CD4 effector immune responses to co-delivered antigen. 
Interestingly, there is significant experimental evidence showing that CT promotes a biased 
Th2 response 155, 156 150, 154. Models using CT as an adjuvant have been associated with 
induction antigen specific IL-4 producing T cells 155, 156, 162 and inhibition of Th1 pro-
inflammatory cytokine production by DC 150, 182, 183. For this reason, CT has been used as an 
adjuvant to sensitise mice to allergens in models of food allergy 184, 185 which are mediated by 
Th2 immunity. However, others claim that CT provides general stimulatory signals that 
result in activation of NFκB in local immune cells leading to production of pro-
inflammatory cytokines 157. Furthermore, DC vaccine studies suggest that CT can promote 
the development of Th1 and Th2 responses simultaneously as DC pulsed with CT and 
antigen induced IFNγ production by antigen specific T cells in vitro 151, 155. Therefore, I was 
interested to assess cytokine production by antigen specific T cells following oral co-
administration of CT and OVA antigen. 
 
In addition to influencing T cell responses, CT has been shown to affect the phenotype and 
functions of intestinal APC 144, 150, 153, 154, 158, 159, 161, 186. In Chapter 4 I showed a proportion of 
intestinal CD103+ DC upregulated the cell surface protein TIM-4 and the activation marker 
CD86 following CT treatment. In light of these observed phenotypic changes, I was 
interested to investigate whether CT treatment also altered the functions of intestinal APC. 
Intestinal CD103+ DC have the specialised capacity to metabolise RA which promotes Treg 
development at steady-state 57, 58. However, in a perturbed state such as in a model of colitis, 
expression of RA metabolising enzyme RALDH is significantly decreased 175. Therefore, I 
was interested to determine what impact oral administration of CT would have on RALDH 
activity among CD103+DC from the intestine and MLN. 
 
In order for intestinal APC to carry out their function as antigen presenting cells they need 
to be able to acquire antigen. Interestingly, previous studies have failed to show antigen 
uptake by CD103+ DC after oral delivery under homeostatic conditions 42, 56. However, 
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following infection with Salmonella, CD103+ DC were shown to migrate to the epithelial 
barrier and take up bacteria 70, 72. Furthermore, administration of CT has been shown to 
promote recruitment of CD103+ DC to the epithelial barrier 158, a location more proximal to 
luminal antigen. Thus, I hypothesised that CD103+ DC, in particular DC that had 
responded to CT by upregulating TIM-4, may have an increased capacity to take up luminal 
antigen following oral administration of CT. 
 
As I was interested to explore functional changes in the APC populations after CT 
treatment, I investigated the role of TIM-4 expression on CD103+ DC. TIM-4 expression 
on Mφ has been shown to bind a number of co-ligands including phosphatidylserine 
(PtdSer) expressed on the surface of apoptotic cells which promotes their uptake 187, 188. 
However, it is not known whether DC expressing TIM-4 obtain the same ability to take up 
apoptotic material. Therefore, I was interested to compare the apoptotic cell uptake capacity 
of CD103+ DC that express TIM-4 following CT treatment to CD103+ TIM-4- DC.   
 
It is clear that oral administration of CT influences the phenotype and functions of intestinal 
immune cells. Thus, in this Chapter, I wanted to investigate the effect of orally administered 
CT on T cell immune responses in the intestine and, specifically, the function of CD103+ 
TIM-4+ DC.  From these studies, I found CT treatment promoted antigen specific T cell 
expansion and production of IL-4. Furthermore, while there was no difference in RALDH 
activity among CD103+ DC isolated from CT treated and untreated mice, the capacity to 
take up apoptotic material ex vivo and antigen in vivo was enhanced among CD103+ DC that 
expressed TIM-4 following CT treatment. Together this data demonstrates that oral 
administration of CT induces functional changes among intestinal APC and induces IL-4 
production by CD4+ T cells.  
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5.2. Aims 
 
Immunisation using CT as an adjuvant had been associated with driving effector T cell 
responses to co-delivered antigen. I have shown CT affects the phenotype of intestinal APC 
however, it is unclear whether this change in phenotype is associated with functional 
changes. Therefore, I was interested to assess how oral administration of CT affects the 
function of intestinal T cells and APC. 
 
Specifically my aims were: 
 
1. To determine how oral administration of CT with antigen affects antigen specific T 
cell expansion and cytokine production in the LP, MLN and spleen. 
 
2. To determine whether CT administration is associated with a change in RALDH 
activity among intestinal APC subsets. 
 
3. To determine if CD103+ DC that have upregulated TIM-4 in response to CT have 
an increased capacity to take up apoptotic cells and antigen. 
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5.3. Results 
 
5.3.1. OVA+CT induces antigen specific T cell proliferation and activation 
 
As CT is a known mucosal adjuvant, I was interested to assess CD4 T cell responses 
following oral administration of OVA antigen with CT. To assess this, mice were injected 
with CD4+ 4C13R OTII cells which express a TCR that specifically recognises the OVA 
peptide OVA323-339 and the fluorescent reporters, AmCyan under the IL-4 promoter and DS-
Red under the IL-13 promoter. One day following T cell transfer, mice were treated with CT 
or OVA+CT by oral gavage. Analysis of T cell proliferation and activation was carried out 
by flow cytometry seven days after transfer as shown in Fig. 5.1. The results show that the 
presence of antigen induced a modest increase in the frequency of transferred cells (as 
determined by CD45.2 staining) among total live cells in the LP and MLN but not the spleen 
(Fig. 5.2, A, C). Furthermore, expression of T cell activation marker CD44 was upregulated 
on transferred cells from OVA+CT treated mice from the LP, MLN and spleen compared 
to transferred cells from CT treated mice (Fig. 5.2, B, D). This data shows that co-
administration of CT and antigen via the oral route induces antigen specific T cell 
proliferation and activation particularly in the LP and MLN.  
 
 
5.3.2. CT increases the frequency of IL-4 producing T cells in the LP, MLN and 
spleen 
 
Immunisation with the adjuvant CT has been reported to preferentially induce 
differentiation of naïve CD4+ T cells to a Th2 phenotype 150, 155, 156. Th2 cells are 
characterised by production of the cytokines IL-4, IL-5 and IL-13. Therefore, I wanted to 
investigate whether oral administration of CT with OVA antigen induced an antigen specific 
Th2 immune response. To address this, I measured the expression of the reporter AmCyan 
expressed by OTII cells 6 days after OVA+CT treatment (Fig. 5.1). The results show that 
IL-4 producing OTII cells could be detected in the LP (Fig. 5.3, C), MLN (Fig. 5.3, A) and 
spleen (Fig. 5.3, B) from mice treated with OVA+CT. However, little to no IL-4 producing 
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cells could be detected among transferred cells from mice treated with CT alone. No IL-13 
expression by the reporter DS-Red could be detected in this experiment (data not shown). 
These results suggest that CT increases the percentage of antigen specific IL-4 producing T 
cells in the LP, MLN and the spleen.  
 
 
 
 
 
 
Figure 5.1: Experimental protocol used to analyse antigen specific T cell responses 
following oral administration of OVA+CT. 
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Figure 5.2: CT increases the frequency and activation of antigen specific T cells in 
the LP and MLN.  
B6 congenic mice were injected i.v. with 5x106 CD45.2+ 4C13R OTII splenocytes enriched by 
magnetic selection. One day later mice were treated with 10µg CT or 50mg OVA+ 10µg CT by oral 
gavage. On day 7, T cells were isolated from the LP, MLN and spleen. Frequency of transferred 
OTII cells among total CD4+ cells is shown on dot plots (A) and graph (C). Expression of CD44 is 
shown on histograms for OVA+CT (solid line) and CT treated mice (dashed line) (B). Graph shows 
CD44 MFI on transferred cells from each tissue (D). Graphs show mean±SEM. Statistical 
significance was determined by Two-Way ANOVA with Bonferroni post-test. *** 0.0001<p<0.001, 
**** p<0.0001 
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Figure 5.3: CT increases the frequency of IL-4 producing antigen specific T cells.  
B6 congenic mice were injected i.v. with 5x106 CD45.2+ 4C13R OTII splenocytes enriched by 
magnetic selection. One day later mice were treated with 10µg CT or 50mg OVA+ 10µg CT by oral 
gavage. On day 7, T cells were isolated from the LP, MLN and spleen and assessed for IL-4 
production by the AmCyan reporter. Representative contour plots show production of IL-4 by OTII 
transferred cells (A). Graph shows percent IL-4+ cells among transferred cells (B) Graphs show 
mean±SEM. Statistical significance was determined by Two-Way ANOVA with Bonferroni post-
test. *** 0.0001<p<0.001, **** p<0.0001 
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5.3.3. CT enhances antigen specific T cell proliferation but not activation 
 
While co-administration of OVA+CT was able to induce T cell proliferation and activation 
compared to administration of CT alone, I wanted to determine whether CT enhanced this 
process compared to administration of antigen alone. Therefore, mice were injected with 
CD4 OTII cells one day before oral administration of CT and OVA in combination or 
alone. On day 6, mice were challenged with OVA antigen by intragastric or intrapertioneal 
routes to boost immune responses (Fig. 5.4). On day 7, MLN and spleen OTII cells were 
analysed by flow cytometry for expansion and activation. The results show that OVA treated 
mice had 0.8-1.8% OTII cells among total CD4+ cells in the MLN compared to 0.8-0.9% 
from mice treated with CT. When OVA and CT were co-administered the frequency of 
OTII cells in the MLN increased to approximately 2.5% in mice challenged intragastrically 
and 1.5% in mice challenged intraperitoneally (Fig. 5.5, A-B). In the spleen, there was no 
significant difference in the frequency of OTII cells between treatment groups. All animals 
treated with OVA antigen showed elevated levels of T cell activation marker CD44 on OTII 
cells isolated from the MLN compared to animals treated with CT alone. Furthermore, 
although the frequency OTII cells in the spleen did not increase after antigen administration, 
CD44 expression was upregulated on splenic OTII cells from OVA and OVA+CT treated 
mice compared to CT treated group (Fig. 5.5, C-D). Together this data shows administration 
of OVA in the presence or absence of CT led to upregulation of CD44 on OTII cells, which 
is a marker of antigen experience, and that the addition of CT promoted a greater expansion 
of antigen specific T cells following antigen administration. 
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Figure 5.4: Experimental protocol used to analyse antigen specific T cell responses 
by intracellular cytokine staining following oral administration of OVA+CT. 
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Figure 5.5: CT enhances antigen specific T cell expansion in the MLN and spleen. 
B6 congenic mice were injected i.v. with 5x106 CD45.2+ OTII splenocytes enriched by magnetic 
selection. One day later mice were treated with 10µg CT or 50mg OVA or a combination by oral 
gavage. On day 6, mice primed with OVA were given a second dose of OVA by oral gavage (50mg) 
or by intraperitoneal injection (100µg). On day 7, the MLN and spleen were analysed for frequency 
of transferred cells and expression of CD44. Representative dot plots (A) and graphs (B) show the 
frequency of transferred cells among total CD4+ cells. Expression of CD44 on transferred cells from 
OVA+CT treated mice challenged i.g. (black solid line), or i.p. (blue solid line), and from OVA 
(dashed grey line) or CT alone (dashed black line) is shown on histograms (C). MFI of CD44 on 
transferred cells is shown on graph (D). Graphs show mean±SEM. Statistical significance was 
determined by Two-Way ANOVA with Bonferroni post-test. * p<0.05 **  0.001<p<0.05 **** 
p<0.0001 
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5.3.4. T cell derived IFNγ and IL-4 could not be detected by ICS following CT 
treatment 
 
In addition to driving Th2 immune responses, reports have shown CT used in a DC vaccine 
context drive both Th1 and Th2 responses 151. This data suggests CT may provide general 
signals to enhance the capacity of DC to drive immune responses. In my study, I observed 
the appearance of an activated population of DC following oral CT, therefore, it was of 
interest to assess IFNγ production by antigen specific T cells in mice treated with OVA+CT. 
To assess cytokine responses, on day 7 mice were injected with Golgi stop agent brefeldin A, 
which blocks release of cytokine from the cell in vivo. Four hours after treatment mice were 
sacrificed and cells from the MLN and spleen were isolated and cytokine production was 
assessed by intracellular cytokine staining (ICS) (Fig. 5.4). The results showed little to no 
production of IFNγ (Fig. 5.6, C-D) or IL-4 (Fig. 5.6, A-B) above background by splenic or 
MLN OTII cells. Therefore, I could not draw any conclusions on the cytokine response 
from this experiment. 
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Figure 5.6: Antigen specific cytokine production could not be detected by ICS 
following oral OVA+CT treatment 
 
B6 congenic mice were injected i.v. with 5x106 CD45.2+ OTII splenocytes enriched by magnetic 
selection. One day later mice were treated with 10µg CT or 50mg OVA or a combination by oral 
gavage. On day 6, mice primed with OVA were given a second dose of OVA by oral gavage (50mg) 
or by intraperitoneal injection (100µg). On day 7, mice were injected with 250µg brefeldin A i.v. to 
prevent release of cytokine from the cell. Four hours later, T cells were isolated from the MLN and 
spleen and assessed for cytokine production by intracellular staining. Representative contour plots 
show assessment of IL-4 (A) and IFNγ (C) production. Frequency of transferred cells producing IL-
4 (B) anf IFNγ (D) are shown on graphs. Graphs show mean±SEM. Statistical significance was 
determined by Two-Way ANOVA with Bonferroni post-test. * p<0.05 **  0.001<p<0.05 
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5.3.5. RALDH activity does not change following oral administration of CT 
 
Activity of RALDH is required for CD103+ DC to metabolise RA from vitamin A 
derivatives. At steady-state, RA production by intestinal DC is important for promoting the 
differentiation of Tregs and maintaining tolerance. Following CT treatment, Treg numbers 
have been shown to decrease and effector T cell numbers increase 60. Therefore, it was of 
interest to compare CD103+ DC RALDH activity between steady-state and following CT 
treatment using the flow cytometry ALDEFLUOR™ assay. I found CT treatment did not 
affect RALDH activity as approximately 75% of CD103+ CD11b+ DC from the LP of 
naïve and OVA+CT treated mice expressed RALDH (Fig. 5.7, A). Furthermore, in the 
MLN, a similar frequency of RALDH+ CD103+ CD11b- and CD103+ CD11b+ DC (50-
55% and 60-65% respectively) were seen from naïve and OVA+CT treated mice (Fig.5.7, B). 
This data suggests that CT treatment does not affect the activity of RALDH in intestinal 
DC. 
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Figure 5.7: CT treatment does not change RALDH activity among intestinal APC 
populations 
APC from the LP and MLN were isolated 17 hours following intragastric OVA+CT. RALDH 
activity was determined using the ALDEFLUOR staining kit and is shown for each subset from 
naïve (pale line) and OVA+CT treated (bold line) mice compared to cells treated with RALDH 
inhibitor diethylaminobenzlaldehyde (DEAB) (shaded). Bar graph shows percent RALDH positive 
for each APC subset from LP (A) and MLN (B). Data was pooled from two independent 
experiments. Graph showed mean ± SEM. 
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5.3.6. CD103+ TIM-4+ DC show an increased capacity to take up apoptotic cells 
compared to CD103+ TIM-4- DC ex vivo 
 
TIM-4 has been shown to bind PtdSer and assists with the uptake of apoptotic cells 187, 188. 
Therefore, I wanted to determine if TIM-4 expression on CD103+ DC in the LP and MLN 
from CT treated mice was associated with an increased capacity for these cells to take up 
apoptotic cells. To address this, cells were isolated from the LP and MLN 17 hours post 
OVA+CT treatment and CD11c+ cells were enriched by positive magnetic selection using 
an AutoMACS system. LP and MLN preparations were enriched for populations of interest 
and to minimise background staining. Apoptotic cell uptake was measured in CD11c+ cells 
that were co-cultured with e670 labelled apoptotic thymocytes. Staining of thymocytes with 
apoptotic cell markers Annexin-V and PI confirmed that 92% of thymocytes were 
undergoing apoptosis prior to co-culture (Fig. 5.8, A). CD11c+ APC were assessed for e670 
expression by flow cytometry after one hour of culture. I found that live cells were enriched 
for FSC-Ahi SSC-Ahi CD11c+ MHCII+ cells which indicates that the magnetic enrichment 
successfully isolated APC of interest. However, APC with low to intermediate expression of 
CD11c, such as CD103- TIM-4+ and CD103- TIM-4- cells, may not have been labelled with 
the magnetic beads to the same efficiency as CD11chi expressing populations as the 
enrichment had a disproportionately high number of CD103+ cells compared to CD103- 
(Fig. 5.8, B). Assessment of individual APC subsets from the LP showed approximately 85% 
of CD103+ TIM-4+ DC acquired apoptotic thymocytes compared to 60% of CD103+ 
TIM-4- DC (Fig. 5.9, A). Although not statistically significant, approximately 95% of 
CD103+ TIM-4+ DC from MLN acquired apoptotic thymocytes compared to 55% of 
CD103+ TIM-4- DC (Fig. 5.9, B). Furthermore, approximately 95% of CD103- TIM-4+ 
Mφ and 70% of CD103- TIM-4- cells from the LP acquired apoptotic material following co-
culture whereas only 15-20% of CD11b- DC from the MLN acquired apoptotic material. In 
summary, this data suggests that expression of TIM-4 on DC allows an increased frequency 
of DC to acquire apoptotic material ex vivo. 
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Figure 5.9: CD103+ TIM-4+ show an increased capacity for apoptotic cell uptake 
compared to CD103+ TIM-4- DC.  
Apoptosis was induced in thymocytes labelled with e670 dye by incubating in 10µM dexamethasone 
for 4 hours. CD11c+ cells isolated from OVA+CT treated mice were enriched by magnetic selection 
and cultured for 1 hour at 1:50 ratio with labeled apoptotic thymocytes. Apoptotic cell uptake 
capacity was determined by flow cytometry. Representative histograms show apoptotic cell uptake by 
DC subsets from the LP (A) and MLN (B). Data pooled from two individual experiments is shown 
on bar graphs. Graphs show mean±SEM. Statistical significance was determined by One-Way 
ANOVA with Bonferroni post-test. * p<0.05 
Figure 5.8: Dexamethasone induces apoptosis in thymocytes and  CD11c+ positive 
magnetic enrichment preferentially enriches for CD103+ DC in the LP and MLN 
 
Thymocytes from 4 week old mice were processed into a single cell suspension and labelled with 
proliferation dye e670. Apoptosis was induced by incubating thymocytes in 10µM dexamethsone for 
4 hours, after which apoptosis was confirmed by Annexin-V and PI staining (A). Cells isolated from 
the LP and MLN of OVA+CT treated mice were enriched for CD11c+ cells by positive magnetic 
selection and co-cultured with e670 labelled apoptotic thymocytes. Dot plots show gating strategy for 
assessing individual APC populations for e670 fluorescence from the LP (B) and MLN (C). 
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5.3.7. TIM-4 upregulation by CD103+ DC modestly increases antigen uptake 
capacity 
 
To date, antigen uptake by CD103+ DC in the LP has not been detected during steady-state 
56, however, it is unclear whether these cells are able to acquire antigen following maturation. 
CD103+ TIM-4+ DC showed an increased capacity for apoptotic cell uptake, therefore, I 
hypothesised that LP CD103+ TIM-4+ DC may be more efficient at the uptake of orally 
administered antigen compared to CD103+ TIM-4- DC. To address this question, mice 
were pre-treated with CT by oral gavage to induce TIM-4 upregulation on CD103+ DC. At 
the peak accumulation of CD103+ TIM-4+ cells (17 hours), mice were fed OVA labelled 
with the fluorescent dye AF647 (OVA-AF647) and sacrificed one hour later to visualise 
antigen uptake by LP cells. The data shows approximately 1.5% of CD103+ TIM-4+ DC 
acquired AF647 fluorescence compared to 0.8% of CD103+ TIM-4- DC (Fig. 5.10). 
Furthermore, as an indication of the quantity of antigen within the cell, I assessed the AF647 
MFI among AF647+ APC. On average, I found CD103+ TIM-4+ cells had an AF647 MFI 
of 300 whereas CD103+ TIM-4- cells had an AF647 MFI of 100. Interestingly, CD103- 
TIM-4+ Mφ had an AF647 MFI of approximately 450 compared to CD103- TIM-4- cells 
which had an AF647 MFI of 175. This data suggests that CD103+ DC that express TIM-4 
in response to CT, have an increased capacity for antigen uptake compared to CD103+ 
TIM-4- DC. 
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Figure 5.10: TIM-4 upregulation by CD103+ DC modestly increases antigen uptake 
capacity in vivo.  
Mice were pre-treated with 10µg CT in bicarbonate buffer by oral gavage to induce TIM-4 
upregulation. Mice were subsequently fed 50mg OVA or 250µg OVA-AF647 in bicarbonate buffer 
17 hours after initial CT treatment. LP cells were isolated one hour after OVA feeding and analysed 
for AF647 fluorescence by flow cytometry. Contour plots show AF647 fluorescence among DC 
subsets from the LP (A). Bar graph shows percent AF647+ cells among total CD11c+ MHCII+ cells 
from the LP (B) and AF647 MFI among AF647+ cells from each APC population (C). MFI value 
was calculated by subtracting average background fluorescence as determined from OVA treated 
mice. Graphs show mean±SEM. Statistical significance was determined by Two-Way ANOVA with 
Bonferroni post-test. **  0.001<p<0.05 
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5.4. Discussion  
 
In this Chapter I show that co-administration of OVA antigen and CT promoted antigen 
specific T cell expansion and production of the cytokine IL-4 and led to functional changes 
in intestinal CD103+ DC that express TIM-4 following CT treatment. I hypothesised that 
activation of antigen specific immune responses to OVA in the presence of CT may result 
from a functional change within APC subsets in the intestine. To investigate this hypothesis, 
I focussed on the CD103+ DC population which I showed to upregulate TIM-4 and CD86 
following CT treatment. As TIM-4 is a receptor for PtdSer expressed on apoptotic cells and 
is required for apoptotic cell uptake 187,  I was interested to investigate the capacity of 
CD103+ TIM-4+ DC to firstly take up apoptotic cells and secondly to take up antigen. I 
found that CT treatment resulted in a modest increase in the capacity of CD103+ TIM-4+ 
DC to take up apoptotic cells ex vivo and antigen in vivo compared to CD103+ TIM-4- cells. 
In addition, as CD103+ DC have been shown to have a specialised ability to promote the 
differentiation of Tregs through their production of RA, it was of interest to determine 
whether this activity was altered after CT treatment. To investigate this, CD103+ DC were 
analysed for the expression of RALDH, an enzyme involved in RA metabolism. 
Interestingly, CT treatment did not result in a significant change in RALDH activity by 
CD103+ DC from steady-state. Although RALDH is well known for its role in RA 
production and the development of Tregs, it is possible that it does not alter the ability of 
DC to drive other immune responses. Overall, this data shows that oral administration of 
CT induces some functional changes among intestinal T cells and, specifically, CD103+ DC 
that express TIM-4. Therefore, I propose CD103+ TIM-4+ DC may be a suitable candidate 
for future study into the promotion of effector T cell responses following oral 
administration of CT. 
 
 
5.4.1. CT enhances antigen specific T cell proliferation 
 
Adjuvants such as CT, are used to potentiate immune responses to co-delivered antigen in 
vaccination settings. Therefore, I hypothesised that oral co-administration of OVA antigen 
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with CT would enhance antigen specific T cell expansion. In line with this hypothesis, I 
found that oral administration of OVA+CT increased the frequency of antigen specific T 
cells present in the MLN compared to administration of antigen alone. As equal numbers of 
OTII cells were transferred at the start of the experiment, this result suggests that the OTII 
cells have proliferated more extensively in mice treated with OVA+CT compared to mice 
treated with OVA alone. Interestingly, OTII cells from OVA+CT and OVA treated mice 
had comparable expression of CD44 which indicates similar T cell antigen experience. This 
suggests CT was not required for OVA protein to be taken up by LP APC and presented to 
antigen specific T cells. Furthermore, mice treated with CT alone had significantly lower 
expression of CD44 compared to mice that received OVA. This observation supports the 
finding that CD44 expressed by OTII cells from OVA treated mice is indicative of antigen 
experience rather than an artefact of the adoptive transfer. Overall, these results suggest that 
OTII cells have similar opportunity to interact with antigen regardless of the presence of CT. 
However, CT has the capacity to enhance antigen specific T cell expansion in the MLN. 
 
5.4.2. CT increases the frequency of IL-4 producing T cells in the intestine and 
spleen 
 
CT is commonly used as an adjuvant in models of food allergy because it has been shown to 
drive differentiation of naïve CD4 T cells to Th2 cells 155, 156, 189. Therefore, I hypothesised 
that following oral administration of OVA+CT there would be an increase in the frequency 
of antigen specific T cells producing the Th2 cytokine IL-4 compared to Th1 cytokine IFNγ.  
 
Importantly, for the detection of IL-4 production I had access to a transgenic mouse in 
which cells express the fluorescent reporter AmCyan when IL-4 message is transcribed, thus 
providing a powerful tool for the sensitive and accurate measurement of IL-4 producing 
cells. Using this technique I found that oral administration of OVA antigen and CT resulted 
in a significant increase in antigen specific T cells expressing AmCyan in the LP, MLN and 
spleen. 
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Since I did not have access to IFNγ reporter mice, I assessed T cell production of this 
cytokine by ICS after in vivo treatment with brefeldin A. However, I could not detect 
production of this cytokine above background staining. Likewise, assessment of IL-4 by this 
method yielded no detectable increase above background staining. IL-4 protein is quickly 
degraded after release whereas signal from a fluorescent reporter can be detectable long after 
transcription 190. Thus, in this context, data from IL-4 reporter mice is likely to be more 
sensitive than ICS. Overall, from these studies, it is not clear whether there is antigen specific 
T cell production of IFNγ however, results from reporter mice suggest that orally 
administered CT can induce antigen specific T cell production of IL-4.  
 
 
5.4.3. CT does not affect RALDH activity among LP and MLN APC 
 
Initiation of immune responses in the intestine has been associated with a corresponding 
decrease in activity of the RA metabolising enzyme RALDH among CD103+ DC. RA plays 
a key role in promoting differentiation of Tregs at steady-state, therefore, it has been 
suggested that loss of RALDH activity may be involved in the initiation of effector T cell 
responses 175. In Chapter 4, I showed CD103+ TIM-4- and CD103+ TIM-4+ DC had 
similar RALDH activity, indicating that DC that express TIM-4 did not have an impaired 
capacity for RA metabolism. As I observed antigen specific T cell expansion and IL-4 
production as opposed to a tolerised response following oral OVA+CT, I hypothesised that 
there would be an overall decrease in the activity of RALDH among APC from the LP and 
MLN. However, in contrast to this hypothesis, I could not detect any overall difference in 
the activity of RALDH between CD103+ DC from the LP and MLN of naïve and CT 
treated mice. Therefore, this data suggests that APC RALDH activity does not impair the 
ability of APC to drive effector T cell responses after CT treatment. 
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5.4.4. CD103+ TIM-4+ DC have an increased capacity for apoptotic cell uptake ex 
vivo compared to CD103+ TIM-4- DC 
 
Accumulating evidence has shown TIM-4 binds PtdSer on the surface of apoptotic cells and 
assists with their capture and uptake 187, 188. Therefore, I hypothesised that CD103+ TIM-4+ 
DC that are detected following oral administration of CT will have an increased capacity for 
apoptotic cell uptake compared to CD103+ TIM-4- DC. In support of this, I found, using 
an in vitro phagocytosis assay, that a higher frequency of CD103+ TIM-4+ DC from the LP 
and MLN took up apoptotic material compared to CD103+ TIM-4- DC. Although, all 
CD11c+ cells showed some capacity for apoptotic cell capture, this was most likely due to 
the large excess of apoptotic cells added to the culture. Once cells begin to undergo 
apoptosis they clump and become difficult to count, therefore, more apoptotic cells were 
possibly added to the co-culture with DC than what was required. Overall, expression of 
TIM-4 by CD103+ DC appears to increase their ability to take up apoptotic cells ex vivo. 
 
 
5.4.5. CD103+ TIM-4+ DC have a modest increase in capacity for antigen uptake in 
vivo compared to CD103+ TIM-4- DC 
 
Immune responses to oral antigen requires antigen uptake by APC in the LP, followed by 
the transport of antigen to the draining lymph node 111. Interestingly previous studies have 
only detected antigen within the CX3CR1+ APC population, which are not thought to 
migrate to the draining lymph node 42, 56. I hypothesised that CT treatment may alter the 
ability of CD103+ DC, in particular the more activated CD103+ TIM-4+ DC, to take up 
antigen. To investigate this, I measured expression of fluorescent OVA (OVA-AF647) 
among APC subsets in the LP. In support of my hypothesis, my data showed a small 
frequency of CD103+ TIM-4+ DC expressing OVA-AF647 whereas CD103+ TIM-4- DC 
did not show any expression of OVA-AF647. Overall, this data suggests that CD103+ DC 
that express TIM-4 after CT treatment may gain some capacity to take up luminal antigen in 
vivo.  
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5.5. Conclusions 
 
In this Chapter I show that in addition to altering CD103+ DC phenotype CT induces 
functional changes in this population. While I found no change in RALDH activity, 
CD103+ DC that express TIM-4 were more effective at apoptotic cell uptake ex vivo and 
acquired a modest capacity for antigen uptake in vivo. Thus, expression of TIM-4 appears to 
be associated with different functional capacities to CD103+ TIM-4- DC. Furthermore, I 
found CT promoted the expansion of antigen specific T cells and led to a Th2 immune 
response in the intestine which was characterised by an increase in the frequency of IL-4 
producing T cells.  Therefore, alterations in DC phenotype and function may contribute to 
the development of immunity to CT in the intestine.  
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6.1. Summary of findings 
 
In this thesis I show a novel method of identifying DC and Mφ populations from the jejunal 
LP and MLN at steady-state. Secondly, using this method I identified a proportion of jejunal 
LP APC that alter their morphology, phenotype and function following oral administration 
of the mucosal adjuvant CT. This population can be identified by co-expression of cell 
surface markers CD103 and TIM-4 and shows elevated expression of co-stimulatory 
molecule CD86. Thirdly, I found CD103+ TIM-4+ DC to have an increased capacity for 
apoptotic cell uptake and some increased ability to take up antigen, suggesting that these 
cells are somewhat functionally distinct from steady-state CD103+ DC. In addition, it 
appears CD103+ DC that upregulate TIM-4 maintain their capacity to migrate to the MLN 
and thus may contribute to the generation of T cell responses. Lastly, I found oral 
administration of OVA+CT to be associated with an increase in frequency of antigen 
specific IL-4 producing T cells in the intestine and spleen. Therefore, I propose CD103+ 
TIM-4+ DC may be contributing to the adjuvant activity of CT, although, the mechanisms 
which lead to the appearance of this population and the mechanisms by which these DC 
alter immune function is yet to be explored. Understanding how CD103+ TIM-4+ DC 
contribute to the development of intestinal immunity will provide insight into the 
mechanisms that lead to the development of effector responses.  
Chapter 6: General Discussion 
 
123 
6.2. Discussion 
 
6.2.1. Phenotype of intestinal APC 
 
Intestinal APC identified by expression of CD11c and MHCII consist of a mixture of DC 
and Mφ. Intestinal APC have been broadly classified into two populations: CD103+ and 
CX3CR1+, which represent DC and Mφ populations respectively (see Section 1.3) 
42, 101. In 
this thesis I highlighted the heterogeneity of intestinal APC populations which cannot be 
appreciated using the current classification system. Recent reviews support this 
interpretation, with a number of authors emphasising the complexity of intestinal APC 
populations and oversimplification of the phenotypic characterisations used in many studies 
191, 192. 
 
In my studies I focussed on CD11b+ APC which make up the majority of CD11c+ 
MHCII+ cells in the jejunal LP. At steady-state, I found CD11b+ APC can be grouped into 
three distinct populations by assessing the cell surface markers CD103 and TIM-4. 
Specifically these were CD103+ TIM-4-, CD103- TIM-4- and CD103- TIM-4+ (see Section 
3.3.2). Interestingly, following oral administration of CT, I observed a fourth population of 
CD11b+ APC that co-express CD103 and TIM-4 (see Section 4.3.1.). I concluded from 
further phenotypic study that CD103+ TIM-4- DC closely resembled the previously 
characterised CD103+ DC which promote Treg differentiation through production of RA 57, 
58. Similar to published reports I found CD103+ TIM-4- DC to lack expression of Mφ 
markers F4/80 42, CX3CR1 
42, 101 and CD64 113 and have high activity of the RA metabolising 
enzyme RALDH 57, 58. Importantly, I found the CD103+ TIM-4+ cells that appeared 
following CT treatment to share these characteristics. This strongly suggests that a 
proportion of CD103+ DC upregulate TIM-4 in response to CT (see Section 4.4.1.). This 
finding highlights the highly plastic nature of intestinal DC and the fact immunostimulatory 
agents can alter their phenotype. 
  
Furthermore, I found CD103- TIM-4+ cells to represent the intestinal Mφ population that 
has been previously identified by their expression of CX3CR1. CD103- TIM-4+ cells had a 
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vacuolar cytoplasm that has been shown to be characteristic of CX3CR1+ cells 
101. Also, I 
found CD103- TIM-4+ cells to express Mφ markers F4/80 42, CX3CR1 
42, 101 and CD64 113 
and lacked RALDH 57, 58 activity which is corresponds to the phenotypic descriptions in 
published reports. 
  
In addition to CD103+ TIM-4- and CD103- TIM-4+ populations, I identified a population 
of cells that expressed neither of these markers but still expressed CD11b (CD103- TIM-4-). 
Due to their lack of CD103 expression it is likely this population would have previously 
been included within the CX3CR1+ Mφ population. I found CD103- TIM-4- cells to consist 
of both DC and Mφ as there was varying expression of F4/80, CX3CR1, CD64 and RALDH 
(see Section 3.4.1). These findings are supported by a recent paper which showed a 
proportion of CX3CR1+ cells to express the DC specific protein zBTB46 
103. Furthermore, a 
small population of CX3CR1
int, which are derived from blood monocytes 99, have been 
reported in the LP at steady-state 42. It is possible that a constituent of the CD103- TIM-4- 
population includes these CX3CR1
int cells. 
 
Finally, in terms of translational applications, it is important to note that APC populations 
described in mice are similar, phenotypically and functionally, to APC populations described 
in humans (see Table 2) 109, 113, 193. A recent study provided significant support for this finding 
by showing a comprehensive transcriptional and functional comparison between jejunal LP 
DC from mice and humans 193. As in mice, the predominant DC population found in the 
jejunal LP at steady-state are CD103+ CD11b+. Due to the highly conserved phenotype and 
functions of intestinal APC between mice and humans, the findings reported in this thesis 
such as the changes in phenotype, function and morphology to CD103+ CD11b+ DC upon 
stimulation with CT are relevant to understanding how intestinal immune responses are 
initiated in humans. 
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Table 2: Summary of the phenotype and function of intestinal APC from mice and 
humans 
 
 
Cell 
type 
 
 
Mouse 
phenotype 42, 101 
 
Human 
phenotype 193 
 
Functional characteristics 
 
DC 
 
CD103+ 
CX3CR1- 
CD11b- 
 
CD103+ 
CX3CR1-  
CD11b- 
Sirpα- 
 
Migratory capacity (CCR7+) in mice 111 
and humans 193. 
Promote gut tropism in mice 81 and 
humans 109, 193. 
Promote Treg differentiation in mice 81. 
Promote Th17 differentiation in humans 193. 
 
 
DC 
 
CD103+ 
CX3CR1- 
CD11b+ 
 
CD103+ 
CX3CR1-  
CD11b+ 
Sirpα+ 
 
Migratory capacity (CCR7+) in mice 111 
and humans 193. 
Have high RALDH activity and promote 
Treg differentiation and gut tropism in 
mice 57, 58, 81 and humans 109, 193. 
Promote Th17 differentiation in mice 81, 
108and humans 193. 
 
 
moDC 
 
CD103- 
CX3CR1
int 
CD11b+ 
 
CD103-  
CX3CR1
int  
CD11b+ 
Sirpα+ 
 
Migratory capacity (CCR7+) in mice 99 
and humans 193. 
Promote Th1 differentiation in mice 114 
and humans 193. 
Have high RALDH activity and promote Treg 
differentiation in humans 193. 
Increase in frequency during 
inflammation in mice 114 and humans 193. 
 
 
Mφ 
 
CD103- 
CX3CR1
hi 
CD11b+ 
 
 
CD103-  
CX3CR1
hi  
CD14+ 
(CD64+?)113 
 
Antigen capture in mice 42, 56, 75. 
Maintain tolerogenic environment 
through production of IL-10 in mice 60. 
Function in humans requires further 
investigation. 
 
 
Italics indicate functional differences between mice and humans. 
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6.2.2. The direct and indirect effects of CT on APC phenotype and function 
 
CT is a potent mucosal adjuvant that is thought to drive effector T cell responses by 
influencing the phenotype and function of APC by direct and indirect mechanisms 86, 144, 153, 
158, 159, 160, 161. However, it is not clear whether oral administration of CT influences intestinal 
APC phenotype by direct or indirect interactions to promote T cell expansion and cytokine 
production in the MLN. Therefore, it is of interest to understand the mechanisms by which 
CT influences the upregulation of TIM-4 and CD86 on CD103+ DC in the LP.  
 
In order to have a direct effect on DC CT would need to bind specifically to a receptor on 
the cell surface. One published report suggested CT induced DC maturation and TIM-4 
upregulation through TLR4 signalling in vitro. In this report, DC from CT and antigen 
treated TLR4-/- mice were unable to induce anaphylactic responses when adoptively 
transferred into naïve wildtype mice whereas CT primed DC from wildtype mice could 144. 
Conversely, C3H/HeJ mice, which have a natural defect in TLR4 signalling 194, develop 
anaphylaxis in response to antigen co-delivered with CT 89, 195, 196. Thus, the requirement for 
TLR4 by DC to respond to CT is not clear. In my study, the expression of TIM-4 and CD86 
by CD103+ DC following oral administration of CT was comparable in TLR4-/- and 
wildtype controls. This suggests that CT does not directly interact with DC through TLR4 in 
my model (see Section 4.4.2). 
 
CT may act directly on intestinal DC via receptors other than TLR4 such as GM-1 (Fig. 
6.1.). CT is known to exerts its effects on epithelial cells by binding to surface ganglioside 
receptors (GM-1) 197 and gaining entry to the cellular cytoplasm 150, 151, 152, 153. Therefore, it is 
important to note that BMDC derived from GM-1 deficient mice maintained the capacity to 
mature to LPS but failed to mature in the presence of CT 161. Furthermore, GM-1 expression 
is required for the adjuvant activity of CT as GM-1 deficient mice were unable to mount 
immune responses to antigen co-delivered with CT 161. These studies suggest that the most 
likely direct target for CT on DC is GM-1 and not PRRs. In further support of this 
hypothesis, a recent study utilising bone marrow chimera mice which lack GM-1 only on 
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haematopoietic cells shows that GM-1 expression on DC is required for DC maturation in 
response to CT and the induction of intestinal immunity to antigen co-delivered with CT 160. 
 
Alternatively, CT may influence the phenotype and function of CD103+ DC indirectly by 
one of two mechanisms (Fig. 6.1.). Firstly, CT is known to cause epithelial barrier 
dysfunction 177 which allows for commensals to populate the LP where they can interact with 
APC through TLRs and other PRRs. In Chapter 4, I show depletion of commensals with 
antibiotics did not prevent upregulation of TIM-4 and CD86 by CD103+ DC. Furthermore, 
as mentioned above, TLR4 deficiency did not affect the ability of CD103+ DC to upregulate 
TIM-4 in response to CT. Therefore, I concluded that CT induced barrier dysfunction was 
not involved in altering DC phenotype following CT treatment (see Section 4.4.2). Secondly, 
CT may be influencing other cells to produce cytokines which affect DC phenotype and 
function. As intestinal epithelial cells are the primary target for CT 150, 151, 152 and act as 
integrators, relaying messages from the lumen to direct LP DC phenotype and function 54, 198, 
199, it is likely they would be involved in any cytokine production induced by CT. CT 
treatment has been associated with activation of MAP kinases and NFκB in epithelial cells 200 
and the production of pro-inflammatory cytokines such as IL-6 201, IL-8, TSLP, TNFα and 
GM-CSF 202, 203 and the chemokines CCL2 and CCL20.  An in vitro culture system showed 
that production of these chemical mediators by CT treated epithelial cells induced DC 
recruitment and maturation 202. Thus, it is of interest to further investigate epithelial 
cytokines and the effects they have on intestinal DC. 
 
In addition to epithelial cells, other innate immune cells such as eosinophils 204, mast cells 205 
and innate lymphoid cells (ILC) 205, 206 provide vital signals that contribute to intestinal 
immunity. While these cells have not been directly associated with CT treatment, they have 
been shown to contribute to the development of intestinal immune responses through 
production of cytokines and chemokines in other settings. Therefore, these innate immune 
cells may play a role in promoting DC to drive immunity in the intestine following CT 
treatment. Intestinal eosinophils are present throughout the LP at steady-state 207 and 
accumulate following inflammation, contributing to tissue damage in food allergy 208 and 
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IBD 209. In addition to their own effector functions, it has been suggested eosinophils may 
affect intestinal DC responses through production of a vast array of cytokines and 
chemokines 204 such as eosinophil-derived neurotoxin which has been shown to induce 
maturation and priming of DC to drive antigen specific Th2 responses 210. Intestinal mast 
cells also accumulate during intestinal inflammation and produce pro-inflammatory 
cytokines IL-1β, IL-6 and TNFα in response to danger signals from dying cells and activated 
monocytes 211. Furthermore, recent studies have strongly implicated ILC in a number of 
immune processes in the intestine. A subset of ILC, known as ILC3, has been reported to be 
an important source of GM-CSF 212 and IL-22 213, 214, 215 in the intestine. GM-CSF is a DC 
growth factor that is known to have profound effects differentiation of DC, DC activation 
and functional outcomes 216, 217, 218. IL-22 assists with epithelial cell repair and tissue damage 
from infection as well as promoting production of pro-inflammatory cytokines and 
antimicrobial peptides by epithelial cells 213, 214, 215. 
 
 
6.2.3. Functions of CD103+ CD11b+ DC in the LP and MLN 
 
There is evidence to suggest that CD103+ CD11b+ DC drive Treg and effector T cell 
responses under different conditions 57, 58, 60, 73, 103, 108. However, it is not clear whether these 
distinct immune responses instructed by the DC are mediated by specific subsets of 
CD103+ DC or whether factors from the environment condition DC to carry out specific 
functions. In this thesis I have demonstrated that the appearance of CD103+ TIM-4+ DC 
in the LP and MLN coincides with an increase in frequency of IL-4+ antigen specific T cells 
in the LP, MLN and spleen following oral administration of OVA+CT. I present data in 
Chapter 4 which suggests that CD103+ TIM-4+ are not a distinct population (see Section 
4.4.1.) but rather represent a proportion of the CD103+ population that have responded to 
direct 160 or indirect signals from CT 202 (see Section 6.2.2.). Therefore, I propose that 
CD103+ TIM-4+ DC may be contributing to the development of effector responses to CT 
(Fig. 6.1). The mechanisms by which this is occurring requires further investigation but 
possible factors include changes in DC-T cell signalling via chemical mediators and receptor-
ligand interactions and the presentation of apoptotic material. 
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Soluble mediator interactions between DC and T cells 
 
Importantly, despite the observed phenotypic changes, time course experiments suggest 
CD103+ TIM-4+ DC maintain their capacity to migrate to the MLN and thus have the 
opportunity to interact with T cells. T cell differentiation is primarily driven by cytokine and 
receptor mediated interactions between DC and T cells (see Section 1.1.2). Thus, changes in 
cytokine secretion and cell surface receptors on DC may result in altered T cell responses. 
DC exposed to CT have been shown to alter their cytokine profile with a number of reports 
showing CT to induce DC production of IL-1β 151, 202, IL-6 , TNFα, IL-23 202, RA and TGFβ 
219. Furthermore, CT has been shown to inhibit murine and human DC production of pro-
inflammatory cytokines such as IL-12 and TNFα which is thought to promote the biased 
Th2 responses commonly associated with CT 150, 154, 182, 220. However, others have shown CT 
treated DC can lead to the generation of IL-4, IL-13 and IL-17 producing T cells 202. 
Therefore, it would be of interest to assess the cytokine profile of CD103+ TIM-4+ cells 
compared to steady-state CD103+ TIM-4- cells to determine how CT affects DC cytokine 
profiles in this model.  
 
Furthermore, due to the potential role CD103+ TIM-4+ DC have in inducing effector T cell 
responses it was of interest to consider the role of RA, the chemical mediator associated 
with driving the generation of tolerance promoting Tregs at steady-state. Of note, oral 
administration of CT has been associated with a decrease in the frequency of Tregs in the LP 
60 and decreased RA metabolism has been implicated in the development of effector immune 
responses 175, 212. However, I found steady-state CD103+ CD11b+ DC to have high activity 
of the RA metabolising enzyme RALDH which was maintained following oral CT treatment 
despite the generation of an antigen-specific T cell response. While RA is associated with 
preferentially promoting Treg differentiation in conjunction with TGFβ 57, 58 and inhibiting 
Th17 differentiation 125, 137, recent evidence suggests that RA may also be required for the 
induction of effector T cell responses by playing a role in the regulation of early T cell 
activation 221. In addition, RA is vital for upregulating gut homing receptors α4β7 and CCR9 
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on T cells 128, 222, 223. It is important that following activation by DC that T cells traffic from 
the lymph node to the tissue to exert their effector functions 60. Therefore, as RA is involved 
in a number of aspects of the immune response, the activity of RALDH may need to be 
maintained and production of additional cytokines such as TGFβ and IL-6 may be the key 
factor in determining T cell phenotype.  
 
Receptor mediated interactions between DC and T cells 
 
In addition to cytokines and chemical mediators, receptor mediated interactions have been 
shown to play a role in determining T cell phenotype. In my study, I observed CD103+ DC 
to alter their phenotype by upregulating TIM-4 as well as an increase in the frequency of IL-
4 producing T cells in response to CT. Thus, it is possible that changes in DC cell surface 
markers ultimately lead to the generation of effector T cells that can produce IL-4. Therefore 
it is of interest that the interaction between TIM-4 on DC and TIM-1 on T cells has been 
implicated in driving Th2 responses in vitro and in vivo 144, 147.  Blockade of TIM-4 with a 
monoclonal antibody prevented the induction of the Th2 response 144 suggesting a role for 
TIM-4 in promoting Th2 differentiation. Therefore, investigation of T cell phenotype 
following culture with CD103+ TIM-4- and CD103+ TIM-4+ DC may provide an 
interesting avenue for future studies.  
 
Presentation of apoptotic material 
 
Another possible mechanism by which CT may affect T cell responses is through 
presentation of apoptotic material by DC. CD103+ TIM-4+ DC showed an increased 
capacity to take up apoptotic material ex vivo and may therefore present apoptotic material to 
T cells following migration to the MLN. For the most part, investigations into apoptotic cell 
presentation have been assessed at steady-state which is associated with development of 
tolerance and capture of apoptotic cells by DC has been shown to promote anti-
inflammatory responses including the induction of TGFβ production and inhibition of DC 
maturation 224, 225. In my model, CD103+ DC acquire TIM-4 expression following activation 
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in response to an adjuvant which permits the uptake of apoptotic material. Adoptive transfer 
studies carried out in Chapter 5 show CT enhances expansion of antigen specific T cells to 
oral delivered antigen compared to antigen alone. Thus, it is unlikely uptake of apoptotic 
material by LPDC impairs the effector response. However, it is not known how acquisition 
of apoptotic material following activation would affect T cell differentiation. In vitro studies 
with human cells show that DC that have taken up apoptotic material in an 
immunostimulatory environment can drive Th1 responses by production of IL-12p70 226 
which suggests that presentation of the apoptotic material by activated DC can drive effector 
T cell responses. Therefore, the ability for activated CD103+ DC to acquire apoptotic 
material prior to migration may influence T cell outcomes. 
 
 
6.2.4. Functions of monocyte-derived APC in the LP and MLN 
 
In addition to CD103+ cells which appear to be bona fide DC, there are populations of 
CX3CR1+ DC and Mφ found throughout the LP which develop from blood monocytes 
42, 99. 
It has been suggested that environmental signals dictate the ratio at which CX3CR1
int cells 
and CX3CR1+ Mφ are found in the LP, with inflammatory conditions favouring the 
CX3CR1
int subset 99, 117. Despite these recent advances, the roles of CX3CR1+ cells in the 
development of intestinal effector responses have not been well defined.  
 
Phenotypic studies presented in this thesis show CD103- TIM-4+ cells likely represent the 
reported CX3CR1+ Mφ population which have been shown to play an important role in the 
maintenance of Tregs in the LP through production of IL-10 60. Interestingly, I observed a 
decrease in expression of CX3CR1 on intestinal CD103- TIM-4+ Mφ following CT 
treatment. As F4/80 and TIM-4 expression were maintained despite the decrease in 
expression of CX3CR1, it is unlikely that this observation is due to a change in ratio between 
CX3CR1
int DC and CX3CR1+ Mφ 
99. However, the decrease in CX3CR1 expression is of 
interest because binding of CX3CL1 to CX3CR1 on the surface of Mφ has been shown to 
regulate IL-10 production. Mice deficient in expression of CX3CR1 had reduced numbers of 
Chapter 6: General Discussion 
 
132 
Tregs present in the LP compared to wildtype controls 60. Therefore, this finding may 
indicate intestinal Mφ have a reduced capacity to produce IL-10 and thus favour a more 
immunostimulatory environment in the intestine following CT treatment.  
 
Furthermore, the CD103- TIM-4- population that I detected in the LP appeared to be 
heterogeneous but did consist of some cells with lower expression of CX3CR1, F4/80 and 
CD64. Therefore, the small number of CX3CR1
int cells reported at steady-state 42 may fall 
within this gate. I observed no significant change in the frequency of these cells following 
CT treatment, although, further in depth study is required to specifically assess whether 
CX3CR1
int cells are involved in the generation of effector responses to CT. 
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Figure 6.1: Proposed mechanisms by which CT treatment promotes phenotypic and 
functional changes among intestinal APC and T cells. 
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6.3. Future directions 
 
The intestine is a complex organ that is constantly exposed to foreign antigen. Therefore, 
strict regulation is at play to ensure appropriate immune responses are generated to specific 
antigens. The mechanisms by which immune responses are initiated in infection and disease 
are not well understood. My studies have associated the presence of CD103+ TIM-4+ DC 
in the LP and MLN with the initiation of effector Th2 responses in the intestine and spleen 
following oral administration of CT. However, it is unclear what signals lead to the 
upregulation of TIM-4 by CD103+ DC and whether or how CD103+ TIM-4+ DC 
contribute to the development of Th2 responses in the intestine. In order to gain a better 
understanding of these processes, I believe the following questions should be addressed: 
a) What cytokines and cell types are being induced following CT administration? 
b) How do these factors influence DC phenotype and function? 
c) What APC subset/s and APC derived factors contribute to the initiation of intestinal 
immune responses? 
 
I propose these future studies to investigate the effects of CT on intestinal APC phenotype 
and function: 
 
1. Analysis of LP and MLN cytokine environments following oral administration of CT 
 
 At steady-state, intestinal Mφ secrete IL-10 to maintain Tregs in the intestine. 
Following oral administration of CT the frequency of LP Tregs has been 
found to decrease. In addition, loss of CX3CR1 signalling has been shown to 
decrease capacity of intestinal Mφ to produce IL-10 in vivo 60. Therefore, it 
would be of interest to assess IL-10 production capacity of CD103- TIM-4+ 
Mφ which I observed to downregulate CX3CR1 after CT. This could be 
achieved by ICS following in vitro restimulation. 
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 Intestinal eosinophils, mast cells, ILC and epithelial cells can produce an 
array of cytokines in response to inflammatory stimuli which can influence 
DC priming and the subsequent T cell response.  Therefore, I would like to 
investigate which cytokines are produced following oral CT administration. 
This can be achieved by intestinal punch biopsy Bioplex and ELISA analysis 
of cytokines such as GM-CSF, TSLP, IL-1β, IL-6, IL-22, IL-25 and IL-33. 
 
 CT treatment has been shown to alter DC cytokine profiles in vitro which can 
affect the capacity of DC to drive different T cell responses. Therefore, I 
would like to assess the capacity of intestinal DC to produce cytokine 
following oral administration of OVA. This could be achieved by ICS 
staining or ELISA analysis of DC culture supernatants.  
 
 
 
2. Impact of cytokines on the function of DC subsets 
 
The cytokine environment in the intestine can impact on the function of DC and 
thus affect T cell responses. Therefore, it would be interesting to assess the impact of 
different cytokines on the ability of intestinal DC to drive T cell proliferation and 
differentiation. Potential cytokine candidates could be identified in the experiments 
described above.  
 
 
3. Flow cytometric analysis of innate immune cells present in the LP following oral administration of 
CT 
 
Recent findings have implicated innate cells, other than DC and Mφ, in contributing 
to intestinal immunity, in part, through cytokine production. Changes in the 
intestinal cytokine environment may affect the phenotype and function of DC which 
results in altered T cell response. Therefore, it would be of interest to assess the 
Chapter 6: General Discussion 
 
136 
presence of these cell types in the LP during CT induced inflammation. Experiments 
would include flow cytometric analysis to identify populations of innate cells, 
including eosinophils (CD45, CD127, CCR3, Siglec F 207, 227), mast cells (CD34, 
CD117 (c-kit), FcεR1) and ILC (CD90, CD127, CD132 206) in the LP of naïve mice 
compared to mice treated with CT. 
 
 
4. Genetic comparison of CD103+ TIM-4+ DC to CD103+ TIM-4- DC 
 
I was unable to detect any significant phenotypic differences between CD103+ TIM-
4+ DC and CD103+ TIM-4- DC from cell surface markers analysed by flow 
cytometry. However, I did observe functional and morphological differences 
between these populations. Therefore, it would be of interest to perform a more in-
depth approach such as transcript analysis by real time PCR that would allow the 
analysis of a large number of different molecules. Results from these studies could 
highlight potential differences that contribute to immune activation in vivo.  
 
CD103+ TIM-4+ DC are present in the LP and MLN during the development of 
Th2 responses to CT. Therefore, it would be of interest to compare CD103+ TIM-
4+ DC to CD103+ TIM-4- DC for the expression of Th2 associated markers such 
as OX40L, Jagged 86, IL-4R 162, IL-25R, IL-33Rα 228, 229, TSLPR and STAT6 162. In 
addition, cytokine transcripts could also be assessed.  
 
 
5. In vitro cultures comparing T cell priming abilities of CD103+ TIM-4+ DC to CD103+ TIM-
4- DC 
 
We have shown CD103+ TIM-4+ DC to have an increased capacity for taking up 
apoptotic cells ex vivo compared to their CD103+ TIM-4- counterparts. CD103+ 
TIM-4+ DC appear to maintain their capacity to migrate to the MLN and thus may 
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contribute to T cell responses. Presentation of apoptotic material by mature DC has 
been shown previously to alter immune responses in vitro 226. In addition, it is not 
known what effect acquisition of apoptotic material has on luminal antigen 
presentation. Therefore I would like to investigate whether uptake or presentation of 
apoptotic material alters T cell proliferation and differentiation. This can be achieved 
by assessment of T cell proliferation and differentiation following culture with FACS 
sorted APC subsets. 
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6.4. Final conclusions 
 
In this thesis I showed a novel method of identifying intestinal DC and Mφ at steady-state 
and following administration of a mucosal adjuvant using cell surface expression of CD103 
and TIM-4. In addition, I showed that CT treatment is associated with an increase in IL-4 
producing T cells and the transient presence of a novel phenotype of DC characterised by 
co-expression of CD103 and TIM-4.  Initial studies showed CD103+ TIM-4+ DC conferred 
some functional and morphological differences to steady-state CD103+ TIM-4- DC. 
However, further studies are required to determine the immunological significance of 
CD103+ TIM-4+ DC. The intestine has developed an intricate system involving signalling 
from many cell types to control immune responses. I propose CD103+ TIM-4+ DC do not 
represent a distinct DC population but rather arise due to changes in the intestinal cytokine 
environment. Furthermore, I propose CD103+ TIM-4+ DC may contribute to the adjuvant 
effects of CT. As intestinal APC populations are conserved between mice and humans, 
understanding of the role of CD103+ TIM-4+ DC in influencing intestinal immunity could 
provide insight into pathological processes that lead to diseases such as food allergy and IBD 
in humans. 
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Appendix II: Gating strategy used to identify APC subsets in the MLN 
